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1. INTRODUCTION
Cancer is one of the most dreaded diseases of our time.
Current statistics indicate that of all the people in the
U.S. and Europe, one in six people will die of cancer [1].
Thus, the need for the new treatments is profound.The
principal aim of all forms of cancer thei-apy is to remove or
to destroy the tumor without seriously damaging the host.
This can often be achieved by surgery, radiotherapy,
chemotherapy, immunotherapy, or by a combination of these
methods of intervention.
One of every four living Americans will be stricken by
cancer, and about one-half of those so affected can be cured
by application of the three standard treatments:surgery to
remove discrete masses, radiation to shrink or kill local-
ized cancers that are not amenable to surgery, and
chemotherapy (the systemic injection of drugs to destroy
cancerous growths throughout the body).However, for the
other one-half of the stricken population, these methods are
not successful since in 60 percent of the cases the tumor2
has already metastasized, or spread, by the time cancer is
diagnosed [2].
Metastasis is the process by which cells break away
from the primary tumor site and spread through various path-
ways like the blood circulation and lymph systems to distant
sites within the body, where they take up residence and form
secondary growths.This colonization at distant sites is
called metastasis, and it is the major cause of death from
human malignancies [3].Once metastasis has occurred, the
treatment of cancer by localized methods such as surgery or
radiation therapy is no longer curative since these methods
cannot destroy the multitude of microscopic metastatic
growths, each of which have the capability of growing to
life-threatening size.
Therefore, in such instances, systemic therapy must be
undertaken.Until now, the only way to treat metastatic
cancer is with chemotherapy, administering drugs to patients
in an effort to destroy the tumor cells.However, these
drugs destroy healthy tissue as well as tumors, and provoke
undesirable and even life-threatening, side-effects.The
possibility of treatment by immunotherapy offersa particu-
larly appealing addition to the existing treatments since,
like chemotherapy, it can be delivered systemically tocom-
bat metastases.Moreover, the immune system is selective:
it normally attacks only diseased cells, and ignores healthy
cells.Hence, immunotherapies might be devised that are3
more cancer-specific than chemotherapies, which often kill,
dividing cells somewhat indiscriminately.Thus, in compari-
son to the alternative methods of control, immunotherapy
could be the preferred and most efficient therapy since im-
mune effector cells kill the target cells without the accom-
panying destruction of normal neighborhood cells.
Potential methods of tumor immunotherapy can be classi-
fied in two broad categories:1) active. immunotherapy, or
those that attempt to induce a state of immune responsive-
ness to tumors in the host, and 2) passive (adoptive) im-
munotherapy, or those that can transfer immunologically ac-
tive reagents that mediate an antitumor response directly to
the tumor-bearing host [4].
In animals, the infusion of sufficient numbers of sen-
sitized or activated immune effector cells can cure tumors,
or significantly reduce the extent of metastases [5].A new
era for cancer therapy was marked in 1985 when the National
Cancer Program officially designated cancer biotherapy as
the fourth modality in cancer treatment., The identification
and adoptive transfer of selected subsets of immune cells
with specific antitumor reactivity into tumor-bearingpa-
tients to mediate cancer regression in vivo is a primary
goal of tumor immunology.4
1.1 Review of Literature
The objective of modeling the immune response has been
fully described by Mohler et al.[6] in a comprehensive sur-
vey of systems theory as applied to immunology.Mathe-
matical modeling and identification techniques provide a
concise description of complex dynamic processes and serve
to facilitate understanding of the immune mechanisms.They
also allow the estimation of internal parameters and physio-
logical states that are not directly accessible to measure-
ment.Moreover, mathematical modeling allow for systematic
experimentation and prediction of behaviors.In disease
control, the diagnosis and treatment of disease are the ul-
timate goals and the application of control theory and sig-
nal processing methods can lead to new and more efficient
diagnosis and vaccination policies.
Fundamental research contributions in the treatment of
cancer have been effected in a number of disciplines, in-
cluding medicine, biology, biochemistry, physiology, and im-
munology.Mathematics has also played an incisive role, and
there is evidence that in cancer research, just as in many
other fields of human endeavor, its role, is becoming in-
creasingly more important.
The ultimate aim of the therapist in the treatment of
cancer is the total eradication of all tumor tissues.If
treatment is to administered through immunotherapy, then the5
construct of a mathematical model of the immunological and
cellular processes involved provide an alternative to evolv-
ing the necessary optimal treatment schedules by clinical
trial and error.The development of models for the investi-
gation of the treatment of cancer by immunotherapy is anac-
tive research area.
Since late 1970s, a number of mathematical models of
the interactions between tumor cells and the immune system
have been proposed.Rescigno and Delisi [7] and Grossman
and Berke [8] have presented simple models of the interac-
tions of tumor cells and cytotoxic (killer) T-lymphocytes.
Lefever and Garay [9] have analyzed cell-mediated cytotoxic
reactions against transformed cells and their negativeregu-
lation by blocking factors.Merrill [10] proposed and ana-
lyzed a model of immune surveillance mediated by NK cells.
However, it generally accepted that the immune response to a
tumor involves several effector cells, including T-lympho-
cytes, B-lymphocytes, and macrophages, and simple kinetic
models of the anti-tumor immune response can describe only
one aspect of this complex phenomenon.Therefore, these
models have not been able to provide a comprehensive expla-
nation of all of the complexities of the immune response to
tumors.
More recently, De Boer, Hogeweg, and their associates
[11,12] presented a model of the macrophage T-lymphocyte in-
teractions that generate an antitumor immune response.How-6
ever, consideration of tumor escape mechanisms and natural
killer activity was not included.Therefore, this model is
also not sufficient to explain the complexities of the im-
mune system.
1.2 Outline of the Study
The goals of tumor immunology are 1) to elucidate the
immunological relationship between the host and the tumor
and 2) to utilize the immune response to tumors for the pur-
pose of diagnosis, prophylaxis, and therapy [13].In the
current investigation, a detailed, knowledge-based mathemat-
ical model of the effector mechanism in which the immune
system attacks tumor cells, or cell-mediated immunity (CMI),
is presented.In addition, control of the dynamics of im-
mune surveillance, which is the ultimate goal of tumor im-
munology, is also considered.
The purpose of this investigation is to obtain a better
understanding of human immune processes and their role in
tumor control by means of an integrated program of immune
systems analysis, mathematical modeling and computer simula-
tion which will be coordinated with active experimentation.
Mathematical modeling of tumor immunology can be of notewor-
thy assistance in the development of various therapies for
the treatment of the tumor.Based upon the models derived,
it is possible to develop phenomenological predictionsor
treatment strategies without the sacrifice of animals.7
This study is presented as follows.In Chapter 2, the
tumor immune system is described for the construct of a
mathematical model, and an immunological mathematical model
and the data necessary for simulation are discussed.Chap-
ter 3 includes an analysis of the proposed model.In
Chapter 4, the results of computer simulation are presented
to show that the form of model responses is reasonable by
comparing with the experimental data.Chapter 5 includes
the conclusions drawn from this investigation and a discus-
sion of possible areas of future research.8
2. MATHEMATICAL MODELING OF THE IMMUNE SYSTEM
2.1 Model Description
In this section, the nature of the immune system is de-
scribed from the viewpoint of the requirements for the con-
struction of a mathematical model.
2.1.1 Tumor Antigens
Cancer is a term used to encompass a wide range of
clinical disease states that involve virtually every tissue
type of the body and every stage of differentiation of these
tissues [14].Cancer cells are said to be malignant as they
demonstrate fewer of their normal cellular functions.As
cancer cells become more malignant, they cease participating
in the overall mission of supporting the survival of the or-
ganism as a whole and begin competing with normal cells for
both space and the limited resources that the organism has
available.Because it is capable of successfully competing
with normal cells, it will tend to proliferate more rapidly
than normal cells.Moreover, the tumor cell may express
many antigens not found in differentiated cells.Examples
of these antigens are alpha fetoprotein (AFP) and carcinoem-
bryonic antigen (CEA).The concept of immunity to the es-
tablishment of tumors and the related concept of the9
"immunologic surveillance" of the emergence of new clones of
malignant cells are based on two important hypotheses:
i)Tumor cells differ antigenically from normal cells,
and
ii)host defense mechanisms are capable of recognizing
and exploiting these differences.
Consequently, in order for immunotherapy to be success-
ful, it is apparent that a tumor must be antigenic.In
other words, it must have the ability to stimulate an immune
response which can be inferred to be relevant to tumor re-
jection.If the antigenicity of the tumor is low, im-
munotherapy will have less effect.A weakly antigenic tumor
evokes a weak immune response, and the tumor load will be-
come too large to control by the time a sufficient number
effector cells are generated.
Tumor antigens may be classified into four major cate-
gories [13]:
a)antigens induced by chemical or physical carcino-
gens, which exhibit little or no immunological
cross-reactivity,
b)antigens of virally induced tumors, which exhibit
extensive immunologic cross-reactivity,
c)oncodevelopmental tumor antigens, and
d)antigens of spontaneous tumors.
Note that tumors which arise spontaneously in animals pro-
duce little or no response to antigens.10
The debris of these tumor cells is phagocytosed by
antigen-presenting cells (APC), which cells subsequently
present antigens in an Ia-restricted fashion to T-cells in
order to initiate CMI.
2.1.2 Presentation of Antigens
Although several types of phagocytic cells may be in-
strumental in the degradation of antigens, only the cells of
the mononuclear system can be considered as APC [15,16].
However, not all macrophages are APCs, and only those
macrophages with the I-A or I-E protein on their surface
have the ability to cooperate with Th cells in the formula-
tion of an immune response.In addition, dendritic cells
are also capable of antigen presentation.The stimulation
of T-lymphocytes by antigen has often been described as re-
quiring at least two signals (Fig. 2.1):
a)First signal:binding by the compound receptor of
a T-cell to the Ia-antigen complex on the acces-
sory cell activates the T-cell.
b)Second signal:the process of activation is com-
pleted when the accessory cell delivers a second
signal in the form of the lymphokine interleukin-1
(IL-1).
Although macrophages and dendritic cells are important
sources of IL-1, keratinocytes and other cells are also ca-
pable of producing IL-1 [17].11
T helper cell activation: the
accessory cell presents an ep-
itope to the T cell in the con-
text of la (class II) molecules
of the presenting cell. The
T cell receptor composed of
T4 and Ti (a and f3 chains)
recognizestheIaandthe
epitope. This recognition to-
gether with the T3 complex
constitute the first signal for
the activation of the T helper
cell. The second signal is pro-
vided by IL-I released by the
accessory cell. T cell activa-
tion leads to the appearance
of IL-2 receptors which upon
binding with IL-2 released by
activated T helper cells trig-
ger proliferation and lympho-
kine release.
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Fig. 2.1T-helper cell activation [13].
2.1.3 Release of Lymphokines
After triggering, and concomitant with proliferation,
Th cells release an array of lymphokines with a variety of
functions.Some examples include:
a)Macrophage chemotactic factor (MCF).The MCF has
a positive chemotactic effect on monocytes and
macrophages, causing them to migrate to the site
of the T-cell response.
b)Migration inhibition factor (MIF).The MIF acts
on blood-borne monocytes, causing them to adhere
to the endothelial lining of venules.Although
MIF production is antigen-specific, once it is
produced the inhibition of macrophage occurs in a12
random and non-specific manner, even in the ab-
sence of antigen.
c)Macrophage activating factor (MAF).The MAF is an
activating factor, with an apparent affect upon
the remaining monocytes which have migrated to the
site of the response.Its role is the activation
of the monocytes into phagocytic cells with in-
creased size, content of lysosomal granules, res-
piratory activity, and ability to ingest particles
and debris in the area.The activation of these
cells increases their ability to kill tumor cells.
Whole tumor cells are not ingested by macrophages,
which rather ingest tumor debris following Tc, NK,
Ma, and ADCC-mediated tumor destruction.
The activation induced by 7-interferon in-
cludes increased size, lysosomal content, phagocy-
tosis, synthesis of membrane-bound antigens, and
the ability to kill ingested organisms.Interfer-
ons (IFN) are antiviral proteins or glycoproteins
produced by several different types of cells in
the mammalian host in response to viral infection:
a) alpha, produced by leukocytes, b) beta, pro-
duced by fibroblasts, and c) gamma, produced by
lymphocytes (Table 2.1).Alpha, or leukocyte IFN,
and fi,or fibroblast, IFN are classified as type I
IFN, while IFN-7 is considered to be type II or13
immune IFN.Type I and type II IFNs can be dis-
tinguished by antibodies raised against prepara-
tions that were thought to be pure [18].IFN
seemingly appears prior to detectable Ma or Ab
(i.e., IFN is an early protective device) and is
protective not only against the inducing virus,
but also against many antigenically unrelated
viruses.
It has been suggested that IFN may also play
a physiologic role in the regulation of the immune
response.It is known that interleukin-2 (IL-2)
induces lymphocytes to produce IFN-7, a type which
is particularly efficient in the induction of tu-
mor cell resistance to the natural killer (NK)
cell-mediated lysis [19].IFN is known to be ca-
pable of suppressing in vitro and in vivo produc-
tion of Ab to a variety of antigens, and is also
capable of inhibiting the induction and expression
of cellular immunity, allograft rejection, the
graft-versus-host rejection, and the induction and
expression of delayed hypersensitivity reactions,
as well as other expressions of cell-mediated im-
munity.
The ability of both NK cells and macrophages
can be augmented by IFN and can be inhibited by
prostaglandins and phorbol esters [18,20].14
Table 2.1The interferons [15]
Cell Source Inducer
a-IFN leukocyte virus, dsRNA
fl -IFN fibroblast virus, dsRNA
7-IFN T-cell Antigen, mitogen
d)Lymphotoxin (LT).Class I restricted cytotoxic T-
cells produce LT in response to nonself class I
antigen.LT is a unique amino acid sequence that
has the ability to kill certain tumor cells, and
IFN may act as an enhancer of LT production in IL-
2 activated T-cells.LT has some sequence homol-
ogy with the tumor necrosis factor (TNFp) and may
have some potential for the treatment of cancers.
TNFa, which is identical to the hormone cachectin,
is produced principally by activated macrophages
and mononuclear phagocytes [21].
e)Interleukin-2.The term "interleukin" has been
used to describe lymphokine molecules which regu-
late the activation and proliferation of white
blood cells.IL-2 was the first of the new im-
munologic hormones to be discovered and character-
ized.Although eight interleukins are currently
recognized by immunologists, the functions of some
remain undetermined or are not connected directly
to immunity systems; in contrast, IL-2 is pivotal15
for the generation of an effective immune re-
sponse.Accordingly, an underStanding of IL-2 and
its receptors opens the way for the development of
therapeutic approaches to a wide range of condi-
tions, including cancer, autoimmune disorders,
chronic infectious diseases, acquired immunodefi-
ciency syndrome (AIDS) and organ transplant rejec-
tion [22].Although all T-cell subsets are capa-
ble of IL-2 production, the Th cell is the major
source.As shown in Fig. 2.1, two signals are re-
quired to stimulate IL-2 production:
1)One, either an antigen or a mitogen; and
2)Two, IL-1 from macrophages. [23].
The major functions of IL-2 are as follows
[24]:
1)inducing lymphokine production by the T-cells,
2)inducing the growth of activated T-cells, thy-
mocytes,
3)inducing cytotoxic T-lymphocyte activity,
4)increasing NK cell activity,
5)increasing lymphokine-activated killer cell
activity, and
6)increasing monocyte cytotoxicity.
By killing those cells that express viral
antigens, the cytotoxic T-cells play a large role
in immunity to viral infections and tumors.In16
addition to the response of activated T-cells to
IL-2, NK cells are a major responding cell.
Fig. 2.2 shows a simple block diagram of the
interactions between interleukin and lymphocytes.
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Fig. 2.2Block diagram of the interactions between
interleukin and lymphocytes.
Proliferation of T-cells is controlled by IL-2 af-
ter an antigen, ingested and presented by a
macrophage, activates individual T-cells. The
antigen stimulates the T-cells to secrete IL-2 and
to make IL-2 receptors.Subsequently, the binding
of IL-2 with its receptors signals the T-cells to
divide, thereby producing pairs of daughter cells
that can also be activated by the antigen.In
this way, a clone of identical antigen specific T-
cells grows until the immune system eliminates the
antigen from the body.17
2.1.4 Effector Cells on Tumor Immunity
The humoral and cellular immune effector mechanisms ca-
pable of destroying tumor cells are summarized in Table 2.2.
The humoral responses to tumor in vivo are still unknown.
Fig. 2.3 shows the activation of T-cells, leading to the re-
lease of lymphokines and to the activation of effector
cells.
Table 2.2Humoral and cellular effector immune mechanisms
in tumor destruction [13].
Humoral Mechanisms
1.Lysis by Ab and Complement
2.Ab and/or Complement-mediated opsonization
3.Ab-mediated loss of tumor cell adhesion
Cellular Mechanisms
1.Destruction by cytotoxic T-cells
2.Ab-dependent, Cell-mediated Cytotoxicity (ADCC)
3.Destruction by activated macrophages
4.Destruction by NK cells
The functions of the effector mechanisms capable of de-
stroying tumor cells include the following:
a)Large granular lymphocytes (LGL).It is likely
that LGL includes cells formerly known as NK
cells.Both IL-2 and IFN have been shown to stim-
ulate the growth and activity of LGL cells.Macrophage
Class IIAccessory Cell
Proliferation
Activation
Lymphokine Release
Recruit and
Activate
Macrophages
IL-2 (Interleukin-2)
MIF(Migration Inhibiting Factor)
MAF (Macrophage Activating Factor)
TNF (Lymphotoxin, Tumor Necrotic Factor)
_... .
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Virally Infected
Cell
Viral
Ant gen
Fig. 2.3Activation of T-cells [13].
Class
LGL cells need no previous exposure to antigens of
the target cell before they become active.Conse-
quently, target cells are more quickly destroyed
by LGL cells than by Tc cells or activated
macrophages.LGL cells are not target or antigen
specific, although their indiscriminate activity
could result from the combined activity of several
LGL subsets, each of which has a restricted target
cell specificity.
In contrast with T-cells, in which IL-2 re-
ceptors have to be induced by mitogens or antigens
in order for the cells to become responsive to IL-
2[25], IL-2 can by itself promote the growth of19
human and murine NK cells.Bonavida [26] proposed
a stimulus-secretion model in which natural killer
cytotoxic factors (NKCF) play a role in the mecha-
nism of natural killer cell-mediated cytotoxicity
(NK CMC).In other words, the soluble cytotoxic
mediators derived from the NK inflict a lethal hit
on the sensitive target cell.
Activation of NK cells does not involve im-
munological memory, and activation can be inhib-
ited by prostaglandin E.
b)Antibody dependent cell-mediated cytotoxicity
(ADCC).ADCC involves the binding of tumor-spe-
cific Ab, which is usually an IgG and may be of
any subclass, to the surface of a tumor.The ef-
fector cell must have surface receptors for the Fc
portion of the IgG.For example, Mo, granulocytes
(in particular, neutrophils), and null cells (K
cells) have these receptors, but platelets and B-
cells do not participate despite their possession
of Fc receptors.
The importance of this mechanism in the de-
struction of tumor cells in vivo remains unclear.
c)Macrophages (M0).Macrophages are indirectly de-
rived from bone marrow promonocytes.After dif-
ferentiation of the promonocytes into blood mono-
cytes, they are settled in the tissues and mature20
into macrophages, where they constitute the
reticulo-endothelial system.Macrophages may be-
come highly cytotoxic when activated by MAF [27-
29], and play an important role in the regulation
of the immune response reaction.Macrophages act
not only as effector cells against tumors, but
also express both positive and negative regulatory
effects on humoral and CMI responses during tumor
growth.These cells are the most active phago-
cytic cells within the human body and are impor-
tant to antigen-presentation.
d)Cytotoxic T-cell (Tc).The T-cells can be divided
into three different subsets:Tc, Th, and Ts.A
viral infection can stimulate a population of
killer T-cells (Tc) which are specifically cyto-
toxic for virus-infected host cells bearing a vi-
ral antigen.The regulation of CMI response is a
complex biological process governed by a series of
positive and negative signals:T-helper cells
(Th) are capable of providing necessary signals
which enhance cytotoxic-T cell proliferation.
T-suppressor (Ts) cells are characterized by the
ability to inhibit the helper function.
The Tc cell recognizes antigen on live, vi-
able tumor cells in the context of a class I MHC
protein, proliferating in response to Th derived21
IL-2.Tc cells do not require assistance from
antigen-presenting macrophages of any type.The
target cells are destroyed by LT and Tc is be-
lieved to be instrumental in "specific" resis-
tance, while the LGL are responsible for the
"nonspecific effects" [30].
The regulatory cell populations can interact
at different levels, for example, in the positive
and negative control of Th or Ts precursor cells,
or at the level of interactions and balance be-
tween fully differentiated Th and Ts effector
cells [31].The network of Ts cells is involved
in the regulation of the Th cells (Fig. 2.4).
Suppressor T-cells produce soluble factors that
mediate suppressive activity.Each Ts subset pro-
duces its own type of suppressive factor, as indi-
cated below [15,32-34]:
1)Antigens from I-A+ and I-J-1- macrophages plus
IL-1 activate the Th cell.I-J1- APC induces
an Lyt-1+Ts1 cell (first-order suppressor,
suppressor inducer), which is a initial cell
of the network of Ts cells.22
Ag
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-Ag
Ia
IL-1
Lyt 1+
IL-2
T Fi(induction) TsF3(effector)
Lyt 1+2+ Lyt 2+
TsF2(activation)
I-J
Fig. 2.4Hypothetical suppressor circuit.
2)The Ts1 cell activates the second-order or
suppressor transducer, the Ts2 cell, by means
of a soluble substances (TsFi) that are acted
upon by anI-J4 macrophage.
3)A soluble factor (TsF2) acts directly on the
final cell in the series, as the effector or
third-order suppressor cell Ts3.This cell is
Lyt 2+
,I-J+and responds to antigen presented
by I-J+ macrophages and the signal from Ts2.
4)The Ts3 cells suppress the Th and Tc cells,
but it is not known whether a single Ts3 cell
can affect all three.23
2.2 Cellular Kinetics
Cellular kinetics are the basis of cell-mediated immune
processes, which have been well-defined from conservation
equations and the principles of chemical mass-action
[35,36].The reaction rate of a substance undergoing a
chemical transformation is proportional to its concentra-
tion, and, if several substances take part in the reaction,
the rate is proportional to the product of the concentra-
tions.In general, the cellular population (or concentra-
tion), xi, is described by
dxi / dt = (source rate - death rate + division rate
+ rate differentiation to - rate differentiation
from)
ith for the .class, or
dxi/dt = vi(t) - xi /7i + pi()xi +ii2pj()pji()xj
-Ji2Pk(.)Pik(.)xk (2-1)
where vi(t) is a source term (from bone marrow via the
blood), ri is a death time constant, and pi(.), pii(.), and
Pik(.) are appropriate growth coefficients (including the
probabilities of stimulatiori and differentiation from one
class to the next).
These coefficients (or probabilities) represent para-
metric feedback control in the immune system of a very com-
plex nature.Indeed, contemporary immunological research to24
a considerable extent focuses upon these. terms, that is, the
manner in which cell production is activated and controlled,
principally by molecularly regulated substances.Conse-
quently, pi(.), phi(.), and pik(.) are primarily functions
of molecular concentrations.They may be deterministic
functions or random processes, dependent upon the approxima-
tions used.
2.3 Mathematical Equation
This section presents a mathematical model of tumor
growth and of the treatment of tumors with immune effector
cells.The humoral responses to tumors in vivo remain un-
known, and it can only be assumed that humoral mechanisms
play no role in the destruction of tumors.Therefore, the
antibody (Ab) is excluded from the model.As may be seen
from this presentation, this assumption does not affect the
qualitative features of conclusions drawn from this investi-
gation.
The block diagram for CMI mechanisms directed against
tumors is shown in Fig. 2.5, and a brief explanation of the
model is provided in this section.As previously noted in
this chapter, immunologic surveillance direct at malignant
cells is based on their antigenicity.The debris from tu-
morous cells is phagocytosed by APCs, which subsequently
present antigens in an Ia-restricted fashion to T-cells to
initiate cell-mediated immunity.The stimulationLGLP
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Fig. 2.5Schematic representation of
antitumor immune response.26
of Th cells requires at least two signals:the antigen and
IL-1.The activation of the T-cells leads to the release of
lymphokines.A major function of IL-2 is to induce the
growth of activated T-cells and NK cell activity since IL-2
induces lymphocytes to produce 1-IFN, an IFN type which is
particularly efficient in inducing tumor cell resistance to
NK cell-mediated lysis.Both IL-2 and IFN have been shown
to stimulate the growth and activity of LGL cells, and
macrophages may become highly cytotoxic once they are acti-
vated by 7-IFN.Differently from the other effector cells,
TcP is stimulated by the tumor cells, and then it is differ-
entiated into Tc.The target cells are specifically de-
stroyed by the LT of the Tc cells and the regulation of the
CMI response is governed by a series of + and - signals by,
respectively, the Th and Ts cells.
Thus, based upon the existing knowledge of tumor im-
munology, a mathematical model of the antitumor immune re-
sponse due to cellular kinetics can be developed.
2.3.1 Cell-Mediated Immune Response. Model
The interaction between a tumor cell and an immune ef-
fector cell resembles an enzyme-substrate reaction.The
rate of chemical changes in biological systems is controlled
by enzymes, a form of biochemical catalyst.When an enzyme
E reacts with its substrate S, an enzyme-substrate complex X
is formed, which in turn decomposes into the original enzymeE and products P of the reaction.The reaction is repre-
sented as
k
E+S4+kl X-+2E+P,
k_i
27
(2-2)
where kl, k2, and k_1 are forward and backward rate con-
stants, respectively.The mass-action equations for the
system are given by:
dE
- - = -k1 E S + k_l X ,
dt
dS
- - = -k1 E S + k...1 X ,
dt
dX
-- = ki E S - k_i X - k2 X ,
dt
dP
...--- =k2 X (2-3)
dt
Similarly, the analogy of cell-mediated cytotoxicity
(CMC) and enzyme-substrate reactions associates the target
cells with substrates and the cytotoxic cells with enzymes
[37].If the number of free effector cells is E, the number
of tumor cells is T, and ET is the number of effector cells
bound to tumor cells and D is the number of lysed tumor
cells, then
and
1(1k2
E + T -* ET - E + D (2-4)
dE
-- = -k1 ET + k2 ET ,
dtdT
= -k1 ET ,
dt
dET
dt
k1 E T - k2 ET ,
dD
-- = k2 ET .
dt
28
(2-5)
Based upon the assumption dET / dt = 0 after a negligi-
ble reaction time, in which the rate of formation and disso-
ciation of the complex ET becomes and then remains very
small in comparison to the rate of changes for T and D
(i.e., the steady-state assumption), the equation can be
rewritten as
and
k E+T-E-I-D, (2-6)
dT
= -k E T ,
dt
dD
-- = k E T .
dt
(2-7)
The rate of tumor lysis is dependent upon the number of ef-
fector cells on the surface of the tumors.The multistage
model for analyzing the cytotoxic reaction occurring within
multicellular conjugates, that is, the mathematical model of
target cell lysis in performed multicellular conjugates that
adequately describes the variability in the lethal hitting29
and target cell disintegration processes, has been developed
by Macken and Perelson [38,39].
The proliferation of tumor cells can be described as:
A
T2T , (2-8)
where A is the replication rate constant.Note that several
deterministic tumor growth models are shown in Appendix 1.
A widely used general deterministic tumor growth model
(based upon Gompertz' growth law) is of the form [40]
dN
dt
K
b N ln(---)
N
(2-9)
whereN(t) = the measure of tumor size (i.e., the number of
tumor cells),
K = the maximum tumor size, and
1 / b = the length of time required for the specific
growth rate to increase by a factor of 1/ e
(i.e., the e-folding time).
The tumor starts from one cell and the tumor dynamics are
shown in Fig. 2.6, which is a sigmoidal curve.
Similar to the cellular concentration model, a per-
turbed tumor cell population, which accounts for the inter-
action between the proliferation of tumor cells and the at-
tack by immune effector cells, takes the following form:
dN
dt
K
= b N ln(---) - kill(.) N ,
N
(2-10)
where kill(.), the parametric control, is a function of Tc,
Ma, LGL, and other concentrations.dn(t)/dt = b n ln(K/n) b = 0.055, K = 3.1 x1012
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Fig. 2.6Tumor growth curve according to Gompertz' growth
law.
Fig. 2.7Equilibrium points.31
When no treatment (i.e., kill(.) = 0)is administered,
the tumor cell grows progressively, assuming the form of
Eqn. (2-9).The equilibrium points are N = 0 or N = K; in
other words, there is no tumor or saturation tumor size.
Then, when treatment is administered,
dN
{c - b In N - kill(.)} N , (2-11)
dt
where c = b in K.The parameters b and K can be estimated
as shown in Appendix 2, and are uniquely determined from
each tumor characteristics.
The equilibrium points are N = 0 or kill(.) = c - b In
N, the first for no tumor and the second for N = exp((c -
kill(.))/ b).The latter situation is shown in Fig. 2.7,
where the number of tumor cells N is plotted against
kill(.), with b and c maintained constant.If the growth
coefficient {c - b in N - kill(.)} > 0, the tumor will also
grow progressively and is in the region below the equilib-
rium point.When kill(.) = 0 (i.e., where there are no im-
mune effector cells), the tumor cell grows progressively,
reaching its maximum size.The equilibrium tumor size de-
creases monotonically according to the increase of kill(.).
In contrast, when {c - b in N - kill(.)} < 0, then tumor
cell will decrease monotonically until dN / dt = 0, corre-
sponding to the upper region of the equilibrium point.If
kill(.)Dc, then the equilibrium tumor size approaches to32
almost 0, which represents the total destruction of the tu-
mor.
Typical cytotoxicity against a TNF/LT concentration
takes the form of a sigmoidal dose-response curve [21,41,42]
(Fig. 2.8).It is assumed that the TNF/LT concentration is
proportional to the population of each cell, and that the
cytotoxicity of Tc and Ma cells is equivalent.The sig-
moidal relationship can then be expressed as [43]:
CTX = CTX0 + ax tanh [fix(x - x0)] , (2-12)
whereCTX = cytotoxicity,
CTX0 = (CTXh + CTX1)/2 ,
CTXh = max. cytotoxicity,
CTX1 = min. cytotoxicity,
ax = (CTXh - CTX1)/2 ,
x = cytotoxin concentration,
ax fix = slope at x0, and
x0 = x value corresponding to CTX0.
The tumor debris of the concentration xd might be
generated to enhance tumor recognition by the immune mecha-
nisms.This can be modeled by the latter term in Eqn.
(2-10), with the removal time constant Td so that
dxd xd
= kill(.) N -
dt Td
(2-13)
The antigen presentation by the activated macrophages
against the antigen concentration follows Michaelis-Menten
dynamics [44](Fig. 2.9).It can be approximated by0.9
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Fig. 2.8Typical cytotoxicity against TNF/LT concentration.
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where xa = concentration of Ma,
zs = APC saturation, and
xdO= antigen value corresponding to zs / 2.
34
(2-14)
One of the major activities of IL-1 is to induce the
synthesis and secretion of the T-cell-derived mitogenic lym-
phokine, IL-2.This link between IL-1 and IL-2 is an essen-
tial element in the T-cell activation sequence since it in-
volves the conversion of a primary macrophage-derived matu-
rational signal into a secondary T-cell-derived prolifera-
tive signal, resulting in the amplification of a specific
immune response.
As noted above (Fig. 2.1), two signals, the presence of
an antigen and IL-1, are required for IL-2 production by the
Th cells.Mizel [45] has determined that the production of
IL-2 is dependent upon IL-1, and that IL-2 is not produced
only in response to an antigen.The experimental data indi-
cated that IL-2 synthesis, when stimulated with IL-1 and mi-
togen, is expressed in sigmoidal form [45].From this ex-
pression, the relationship between IL-1 and IL-2 can be
formulated as follows:
F(.) = {dF + (aF - dF)/[1+(z/cF)kF]1 FTH
and
(2-15)FTH =
Th
Thsat + Th
35
whereF(.) = IL-2 concentration,
z = IL-1 concentration,
aF = min. IL-2 concentration,
dF = max. IL-2 concentration,
kF = slope parameter,
cF = concentration of IL-1 providing 50% of the
maximal response, and
Thsat = T-helper cell saturation.
Activated T-lymphocytes proliferate in response to IL-2
produced by T-helper cells.When an activated T-cell di-
vides, it may remain activated or it may return to the rest-
ing state.This is possibly dependent upon the IL-2 recep-
tor expression on the daughter cells.Milanese [46] has
suggested that the T-cell remains in an activated state, but
returns to the resting state in the absence of additional
antigenic stimulation.The growth response of T-lymphocytes
to IL-2 is accurately described by a four-parameter logistic
function [47-49]:
[aT - dT ]
YT = dT
1+(x/cT)kT
where yT = proliferative response,
x = concentration of IL-2,
aT = min. response,
dT = max. response,
(2-16)kT = slope parameter, and
cT = concentration of IL-2 providing 50% of the
maximal response.
Fig. 2.10 shows the simulation of T-cell proliferationfor
the response of IL-2.
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Fig. 2.10Growth response curve.
36
In a healthy state (i.e., a normal steady-state),a
constant number of lymphocyte precursors cellsare produced
each day.However, the influx of precursors is increased
due to inflammatory reactions in acancerous state.It is
assumed that the inflammatory reaction is quasi-steady
state.Consequently, this cell influx is described by
vi(t) = ui (1 + poi) , (2-17)37
where vi is the cell birth rate at a normal state and poi is
the inflammation rate.
The differentiation of cytotoxic T-cell precursors is
dependent upon contact with tumors and IL-2, and generation
of all precursors may be inhibited by the T-suppressor ef-
fector cells.In turn, the activity of LGL cells can be
augmented by lymphokines such as IFN and IL-2, while macro-
phages (140) may become activated by /-IFN (i.e., MAF).Sev-
eral recent studies have suggested that IL-2 regulates the
generation of 1-IFN [19,50,51].The kinetics of .y -IFN pro-
duction by Th cells stimulated with IL-2 can be expressed in
the same form of sigmoidal relationship previously noted in
this section [50].Therefore, the relationship between 7-
IFN and IL-2 can be expressed by a four-parameter logistic
function,
7-IFN= d-IFN (aIFN dIFN) /[ 1+(F/cIFN)kIFN
] .(2-18)
Both IL-2 and IFN, which are bound with IL-2 Receptor and
other cells (e.g., LGL, M,), respectively, are removed from
the system.However, due to the assumption of the quasi-
steady-state, the removal term is not included.
At present, information about the quantitative rela-
tionships between Ts cells and other immune effector cells
is unavailable.Therefore, it is assumed that the relation-
ships between T-suppressor factor (TSF) and its activity
take the form of typical dose-response curves.This is a38
reasonable assumption since almost all biological system re-
sponses reflect this sigmoidal relationship.
The differential equations for the model considered in
this section are given in Table 2.3.39
Table 2.3Differential equations for the model.
dxl/dt
dx2/dt
dx3/dt
dx4/dt
=
=
=
=
v1(t)
v2(t)
v3(t)
v4(t)
x1/71
"" x2 /T2
- x3/73
- x4 /T4
P16x1P81x1
P27x2P27'x2xll - P82x2
P38x3P83x3
P49x4P49'x4
dx5/dt=v5(t)- x5/75P5,10x5
dx6/dt=p16x1- x6/76P6x6
dx7/dt=p27x2+ p27'x2xli - x7/77 + p7x7
dx8/dt=p38x3- x8/78+ p8x8
dxg /dt=p49x4+ p49'x4- x9/79
dx10 /dt = P5,10x5 x10/710
dxii/dt = Pllx11 x11/711P7,11x11P9,11x11
P10,11x11
dx12/dt = x11/711 + P7,11x11 + P9,11x11 + P10,11x11
x12/712
Notes:
a.x. = state of each cell at a certain time instant.The
subscripts are as follows:1, ThPI 2, TcP; 3, TsP; 4,
LGLP; 5, Mo; 6, Th; 7, Tc; 8, Ts; 9, LGL; 10, Ma; 11,
Tu; and 12, Tu debris.
b.Cell influx:vi(t) = ui(1 + Poi), i = 1,..,5
Inflammation rate:Poi = Pid+(Pia-Pid)/(1+(F/ci)ki
)
IL-1:z = FD(.) x10
FD(.) = (zsx12)/(xdo+x12)
IL-2:F(.) = (dF+(aF-dF)/(1+(z/cF)kF))*(x61/9"hsat+x6))
7-IFN = dIFN4-(aIFN-dIFN)/( 1+(F/cIFN) N]
Differentiation rate:P16 = Al (1
Differentiation rate:p27 = A2
Differentiation rate:p27'= A2 F(.)
Differentiation rate:p38 = A3(1 + F(.))
Differentiation rate:p49 = A4(1 + F(.))
Differentiation rate:p491= A4 7-IFN
Differentiation rate:P5,10 = A5 7-IFN
Suppression rate:P81 7AF = P83 = TsF = dTSF+(aTSF-
dTSF)/(14-(x8/cTSF)- )
Proliferation rate:p6 = p7 = p8 = dT+(aT-
dT)/(1+(F/cT))1"
Tumor growth rate:P11 = b ln(K/x11)
Killing rate:p7 = P9,11 = P10,11 = CTX
Cytotoxicity:CTX = CTX0 + ax tanh[flx(xi-xio)]
(i = 7, 9,10)
c.It is assumed that the inflammation rates for all immune
effector cells are identical.
d.Initial conditions: 41(0) = 1.05 x 108; 42(0) = 2.2 x
10';
7
x3(0) = 2.2 x 10'; 4(0) = 1.3 x 10';5(0) = 1.3
x 10; 6.(0) = 5.25 x 106; 47(0) = 1.1 x 10u;);8(0) =
1.1 x 106; x9(0) = 1.56 x 10°; x10(0) = 6.5 x 10 ;
x11(0)= 1; and x12(0) = 0.001.40
2.3.2 Parameter Values
Ideally, the data which fit the model behavior should
be obtained under identical conditions, for example, from
the same material and the same type of tumor.However, it
is difficult to obtain consistent data, and the parameter
values for the current investigation have been obtained from
a variety of sources.Thus, it is difficult to maintain
consistency when drawing upon data provided from different
experiments.In addition, several parameters remain un-
known.Consequently, the parameter values are chosen some-
what arbitrary.
A typical thymus contains about 200 million cells, and
the thymic cortex produces about 50 million cells each day,
most of which disappear within three days (i.e., Ti = 3
(i=1,2,3) [day]).It may be assumed that 30 percent of
these cells are Tc/s, while the balance are Th [52].The
activated T-lymphocytes are considered to be long-lived
cells.Thus, the turnover time for T-cells is assumed to be
50 days [8].
It has been demonstrated that bone marrow is required
for the proliferation/differentiation of NK cells, which
have a life span of a few weeks.In human peripheral blood,
cells with the NK cell phenotype represent an average of 15
percent of the cells with lymphoid characteristics, subject
to wide individual variations [53].The total number of T-41
cells in the blood is of order 108 cells, therefore, the in-
flux of NK cells is 750,000 cells per day.
Blood monocytes originate in the bone marrow from di-
viding precursor cells.They then enter the peripheral
blood, in which they circulate until they leave it to become
macrophages in the tissues.The normal macrophages in the
tissues consist of 1.5 x 107 cells [54],. which is nearly
consistent with macrophage concentrations of 1 per 10 or 100
T-cells determined in vitro [55].The calculated mean
turnover time for macrophages is about 20 days.Therefore,
the influx of macrophages is approximately 750,000 cells per
day.The turnover time for activated macrophages is assumed
to be short, one day [11].
During inflammatory reactions, the influx of immune ef-
fector cells is assumed to increase by a factor of 10.It
is also assumed that 103 - 107tumor cells per day activate
the lymphocyte, LGL, and the macrophages.Therefore, the
activation rates, Ai, have been set at 10-3 - 10-7 by fit-
ting the model outcome to the experimental results.
The parameter values for the model simulation are shown
in Table 2.4.Table 2.4Model parameter values.
Ti =
74 =
75 =
Ti =
79 =
710
711
712
gi = 0.001
ul = 3.5 X10:
u2 = 7.5 X 10`,"
u3 = 7.5 X 10`"
u4 = 750,000
u5 = 750,000
1 / b = 9.35
k = 2.93 X 10"
CTXh = 10
CTX1 = 0
Px = 0.2
zs = 1
x70 = 7 X 108
x90 = 3 X 107
x100 = 1 X14
xdO =5 X 10."
dF = 1,000
aF = 0.01
kF = 1
cF =
dIFN = 40
aIFN = 5
kIFN = 1
cIFN = 10
pid = 10
Pia = 0
ki = 1
ci = 10
42
3(i=1,2,3) [day] Lymphocyte death time constant
20 [day] LGL F death time constant
20 [day] macrophage death time constant
50 (i=6,7,8)[day] T-cell death time constant
20 [day] LGL death time constant
= 1 [day] Angry macrophage death time
constant
= 1000 [day] Tumor death time constant
= 0.5 [day] Tumor debris removal time
dT = 1
aT = 0
kT = 1
cT = 10
dTSF = 9
kTSF
= 0
Jc-TSF = 1 7
cTSF = 10
Thsat = 5 X 108
[cell/day]
[cell/day]
[cell/day]
[cell/day]
[cell/day]
[cell/day]
[day]
[cells]
[cell/day]
[cell/day]
[cells]
[cells]
[cells]
[cells)
[cells]
[cells]
constant
Activation rate (i=1,..,5)
Lymphocyte birth rate
Lymphocyte birth rate
Lymphocyte birth rate
LGL birth rate
Macrophage birth rate
e-folding time
Max. tumor size
Max. cytotoxicity
Min. cytotoxicity
Slope at x0
APC saturation constant
Te corresponding to CTX0
LGL corresponding to CTX0
Ma corresponding to CTX0
Antigen value corresponding to
zs/2
Max. IL-2 concentration
Min. IL-2 concentration
Slope parameter
Varies according to antigenicity
Max. IFN concentration
Min. IFN concentration
Slope parameter
Concentration of IL-2 giving 50%
of the maximal response
Max. response (i=1,..,5,13)
Min. response (i=1,..,5,13)
Slope factor(i=1,..,5,13)
Concentration of IL-2 giving 50%
of the maximal response
Max. response
Min. response
Slope parameter
Concentration of IL-2 giving 50%
of the maximal response.
Min. response
Max. response
Slope parameter
Concentration of Ts giving 50%
of the maximal response
Th cell saturation43
2.3.3 Compartmental Model
To date, it has been assumed that immune effector cells
are distributed homogeneously throughout the body and that
immune responses, including binding, triggering, prolifera-
tion, and differentiation, also occur throughout the entire
body.However, when a normal cell becomes a malignant cell,
the immune response can be observed only in the tumor re-
gion.Therefore, only a small fraction of the potential
number of effector cells have the ability to recognize the
surface antigen of the tumor cell.
As the effector cells circulate between tumor regions
and normal regions, all effector cells have at least some
probability of eventually encountering a tumor.The effect
of the circulation of effector cells can be modeled by the
consideration of a two compartment system:a tumor compart-
ment and a normal compartment.
These time delay conditions are incorporated by modify-
ing the differential equations shown in Table 2.3.If xis
refers to a particular compartment, s, or an organ with mi-
gration between compartments, then Eqn.(2-1) must include a
net migration term such that
dxis xis
dt
vism - pis()xis 4..E.2p,s(.)pjis(.)xj s
Ti ,t1
k#1
.2pks(.)piks(.)xks
u#s2 Si s u(-)xi
u
rt sSi r s(Oxis (2-19)44
where the superscript s indicates possible dependence upon a
compartment or organ.In general, the migration coeffi-
cients, 6i,s,u() and 6i,r,s(), can be deterministic or
stochastic functions of the appropriate xi(t) since certain
lymphokines manipulate the migration coefficients [35].45
3. ANALYSIS
Because of the presence of inherent stochasticity and
the lack of precise knowledge of a number of variables, the
immune system for killing tumors is treated as a nonlinear
stochastic system.It is evident that the control vari-
ables, including those which are multiplicative or additive,
are nonlinear functions of states.Thus, it is assumed that
the system parameters are uniquely determined from nonlinear
gains.Moreover, each state equation for the CMI mechanism
can be described as a bilinear system (BLS).However, the
total closed system may be synthesized as a BLS with output
feedback (i.e., nonlinear gain) through the controls.Fig.
3.1 shows that the CMI mechanism for killing tumors consists
of a BLS with nonlinear gain [56].The model equation thus
becomes a highly nonlinear system.
3.1 Existence and Uniqueness
In this section, the properties of solutions to the
nonlinear differential equations listed in Table 2.3 are in-
vestigated.
Theorem 1.For all t > 0, the model equations have a
unique solution satisfying the given initial con-
ditions.46
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Fig. 3.1Block diagram of CMI dynamics.
Proof.The general forms of n first-order nonlinear
differential equations (Table 2.3) can be combined
into a first-order vector differential equation.
X(t) = f(X(t), u(t)), t > 0;X(0) = X0 (3-1)
where X(t) E R12 and f :R12x R12,X0 E R12.
At certain time instants, that is dominated by a linear
systei subject to the same initial conditions, whose
solution
Y(t) = [yi(t), y2(t), Y12(t)]' (3-2)
is continuous and exists for all t > 0.Let
X(t) = [Xl(t), X2(t), ,X12(t)]'
and let
f(x) = [fl, f2,
47
(3-3)
(3-4)
be the vector of the right-hand sides of the equations on
[0,8],
and
12
IIX II= .21
IXi I 1=
12
f II= .2 Ifi I 1=1
(3-5)
(3-6)
Because each component of f is continuously differen-
tiable in the neighborhood (0,x0), Eqn.(3-1) has a unique
solution over [0,6] for some sufficiently small 8.It guar-
antees the local existence and uniqueness of the solution
[57].For every finite T, there exists finite constants KT
and hT such that
f(t,x) - f(t,z) KTx - z ,
IIf(t,x0)
II< hT , (3-7)
for all t E [0,T] and x,z E X, written as (t,x),(t,z) E D,
where D is a connected, closed set (t,x),(t,z) E D. For
instance, since the tumor starts from one cell, the tumor
equation (i.e., dx/dt = b x ln(k/x)) satisfies the above
conditions as follows:
k
In
x Yit tk
IfkI Idtt
X
- maxilx1,1171/
y X
k lxylmaxilx1,1y11
lx1lyl
If y < t < x satisfies without loss of generality,
I
k
In I KT yI x y
IInk- Ink l<k lx-Y1 x y
lyl
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where KT = knyl. If tumor cell size x is zero, the system
is a healthy state. In this case, the tumor equation does
not exist. Similarly, it can be shown from the other
components that f satisfies a Lipschitz condition for
positive states and Eqn.(3-1) has a unique solution over
each finite interval [0,T].
Similar to the development in [6], it appears that the
solution to (3-1) is nonnegative for t Z 0 if the initial
state is positive.Since the solutions of the model are
interpreted as populations of cells which can not be
negative, note that a nonnegative solution of the model is
in accord with the biological meaning of the system.49
3.2 Healthy State Stability
For the "healthy state" condition, it may be assumed
that no tumor exists within the body and that no IL-1 is
present since it is a function of tumors (Eqn. 2-6).There-
fore, it may also be assumed that IL-2 is in small quanti-
ties that may be disregarded (Eqn 2-7).Similarly, IFN, in-
flammatory reactions, T-cell suppression, and T-cell prolif-
eration by IL-2 can be disregarded.The model equations
then become:
dx1 /dt = vl - x1/71 - Aix' ,
dx2/dt = v2 - x2/72 - A2x2 ,
dx3/dt = v3 - x3/73 - 113x3 ,
dx4/dt = v4 - x4/74 - A4x4 ,
dx5/dt = v5 - x5/75 ,
dx6/dt = Alx1 - x6/76 ,
dx7/dt = A2x2 - x7/77 ,
dx8/dt = A3x3 - x8/78 ,
dx9/dt = A4x4 - x9/79 ,
dx10/dt = -x10/710 , (3-8)
where xi, i = 1,..,10, represents the state of each cell as
indicated in Table 2.3, and the parameters are equivalent to
those listed in Table 2.4.
The immune system then becomes a linear system without
output feedback as follows:
dx(t)/dt = A x(t) + B U , (3-9)50
where x(t) is an n-dimensional state vector, A is an n x n
matrix, and B is an n dimensional vector.The matrices, A
and B, are as follows:
-1/71-111 0 0 0 0 0 0 0
0-1/72-A2 0 0 0 0 0 0
O 0-1/T3-A3 0 0 0 0 0 0
O 0 0- 1/74 -A4 0 0 0 0 0
A= 0 0 0 0-1/75 0 0 0 0
Ai0 0 0 0 -1/76 0 0 0
O A20 0 0 0 -1/77 0 0
O 0 A30 0 0 0 -1/78 0
O 0 0 A40 0 0 0 -1/79
0 0 0 0 0 0 0 0 -1/T10
b1
b2
b3
b4
B = b5 (3-10)
0
0
0
0
0
where bi, i = 1,...,5, is an appropriate coefficient which
satisfies biu = vi, and is the lymphocyte precursor birth
rate, etc..
In linear time-invariant systems, the equilibrium point
is asymptotically stable iff R(A) < 0 for all eigenvalues
of A [58].Since matrix A is lower triangular, all its
eigenvalues are on the diagonal.Therefore, Eqn. (3-10)
always has negative real-part eigenvalues.Biologically,
this condition is always satisfied and the system is asymp-
totically stable because no tumor exists.51
3.3 Cancerous State Stability
When a tumor is present, in a "cancerous state" condi-
tion, the model is an NLS with output feedback, as described
in Table 2.3.
The relations between the tumor and the immune effector
cells could be approximated to simplify the analysis.Thus,
let x(t) = the tumor and y(t) = the immune effectors, Tc,
LGL, and Ma.Then,
and
k
X = b x ln(---) -
x
x
7
f(x,y)
y
y = A y - g(x,y) , (3-11)
7
where
f(x,y) = the tumor death rate solely due to predation and
g(x,y) = the immune effector cell renewal rate due to
stimulation.
Eventually, to achieve asymptotic stability, the unper-
turbed tumor growth rate should be less than the natural
death rate of the tumor and the rate at which the tumor is
killed by the effector cells.This condition will through
IL-2 induce an increase in the number of effector cells.
However, an excessive amount of IL-2 will cause harmful side
effects (e.g., fevers or headaches) [59] to the patient for
reason of IL-2 toxicity.Therefore, it is important to re-52
strict the amount of IL-2 used in the treatments and
determination of the optimal administration of IL-2 for
tumor control becomes a research objective.
3.4 Controllability
The concept of tumor escape is related to system con-
cepts of controllability.In this section, the techniques
developed for nonlinear systems are used for the analysis.
In addition, selected results related to the controllability
of nonlinear time-varying systems are given in Appendix 2.
As previously noted, the recirculating, antigen-spe-
cific T-cell comes in contact with tumor antigen presented
by an appropriate class II MHC-bearing accessory cell.A
second signal, IL-1, secreted or carried by the accessory
cells, activates the T-cell, whose receptors have bound the
antigen-Ia complex.Activated T-helper cells then secrete
IL-2, a major function of which is to cause the prolifera-
tion of activated T-cells.Therefore, IL-2 is assumed to be
an input signal, stimulating immune system control of tu-
mors.This CMI process leads to the release of lymphokines,
and subsequently to the activation of immune effector cells
that destroy tumors.
Without an enzyme catalyst the system could not attain
the necessary degree of controllability or sustain life,
which makes the need for multiplicative control obvious
[60].IL-2, as the first hormone of the immune system to be53
recognized, helps the body mount a defense against microor-
ganisms by triggering the multiplication of only those cells
that attack the invader.The clinical use of IL-2 prepara-
tion for cancer patients or those with acquired immune defi-
ciency syndrome (AIDS) is considered as an immunotherapeutic
multiplicative control.
IL-2 is produced by the antigenic stimulation of the
immune system in the presence of a tumor.If the tumor
antigenicity is low, the immune system will not recognize
the incidence of a tumor.In this case, the model equations
are identical to those for the healthy state, with the ex-
ception of tumor growth and debris, which has the following
representation:
dx/dt =Ax+Bu, (3-12)
where x E Rn, u E Rm, and the A and B matrices are:
A =
and
-1/71-Al 0 0 0 0 0 0 0 0 0
O-1/72-A2 0 0 0 0 0 0 0 0
O 0-1/73-A3 0 0 0 0 0 0 0
O 0 0-1/74-A4 0 0 0 0 0 0
O 0 0 0- 1/75 -µ50 0 0 0 0 0
Ai0 0 0 0 -1/76 0 0 0 0 0
O A2 0 0 0 0 -1/77 0 0 0 0
O 0 A30 0 0 0 -1/78 0 0 0
O 0 0 A40 0 0 0 -1/79 0 0
O 0 0 0 0 0 0 0 .-1/T100 0
O 0 0 0 0 0 0 0 0p11-/711 0
O 0 0 0 0 0 0 0 01/T11 -1/T1254
b1
b2
b3
b4
b5
B = 0
0
0
0
0
0
0
where bi, i = 1,...,5, is an appropriate proportional coef-
ficient.
In this representation, p11 is the tumor specific
growth rate, which is dependent upon the state x11 to ex-
plain the saturation of the tumor growth.For purposes of
analysis, it is assumed thatp11 is constant, that is,
growth is density independent and exponential.A continu-
ous-time, time-invariant linear system, Eqn. (3-12), with a
dimension n state-space is completely controllable if and
only if rank [B, AB,..., An -1B ]= n.However, in this
case the rank of the controllability matrix is less than n.
Therefore, the immune system with an antigenically low tumor
cannot be controlled.It is clear, since the B matrix has
zero rows, that the corresponding component of the immune
system cannot be affected by any of the control components
and the system is not completely controllable.
In addition, in contrast to the healthy state, the im-
mune system is not asymptotically stable in the sense that
the tumor . 0 as t .- m for any initial value and for zero
input for t > 0.Viz, the real parts of eigenvalues of the55
matrix A are not all negative.The results obtained are co-
incident with the biological meaning of the phenomenon, in
which the tumor grows progressively.
If tumor antigenicity is higher, the tumor stimulates
the immune system.As previously noted in this chapter, the
cell-mediated immune system consists of a BLS with nonlinear
gains.The nonlinear gain (e.g., the multiplicative control
variables) is activated by IL-2.It is assumed that the
multiplicative control variables are proportional to the
stimulation of IL-2.The system thus described by Table 2.3
is said to be nonlinear, time-invariant with linear control,
subject to the following representation:
dx/dt = A(x)x + B(x)u , (3-13)
t E [to,m), where x(t) is an n x 1 state vector, u(t) is an
m x 1 input vector, and A and B are, respectively, n x n and
n x m matrix-valued functions.For the sake of convenience,
the model equations can be rewritten with parameters as
given in Table 2.4.
dx1 /dt = u1(141301) x1/71 P16x1P81x1
dx2/dt = u2(1+p 02) x2/72 - p27x2 - g2ux2x11 - p82x2
dx3/dt = u3(1+p03) - x3/73 - g3x3 - g3ux3 -p83x3 ,
dx4/dt = u4(1 +p04) x4/74 - p4(1+u)x4 - p49'x4
dx5/dt = u5(1+p05) x5/75 P5,10x5 r
dx6/dt= P16x1 x6/76P6x6
dx7/dt = p27x2 + g2ux2x11 - x7/77 + p7x7 ,
dx8/dt = g3x3 + g3ux3 - x8/78 + p8x8 ,dx9/dt = A4x4 + A4ux4 + p49'x4 - x9/79 ,
dx10 /dt = P5,10x5x10/710
dXlildt = PliXilX11/711P7,11x11P9,11x11
P10,11x11
dx12/dt = x11/711P7,11x11P9,11x11P10,11x11
x12/712
56
(3-14)
In sufficiently small neighborhoods of nominal trajec-
tory x
*and u
*
,the nonlinear system can be approximated to
Eqn. (3-13) using perturbation equation-In vector form,
the matrices A(x*) and B(x*) are given by the following
arrays of partial derivatives:
and
A(x*)=
B(x*)=
8f1 aft
axi axn
afn afn
ax1 axn
afl
au
x
*
(3-15)
afn
u au
*
Eqn. (3-12), the immune system with a low antigenic tumor,
is a special case of Eqn. (3-13).
Now, let's check the controllability of the system ex-
pressed in Eqn. (3-15), using the theorems provided in Ap-57
pendix 2.The elements of A(x*) and B(x*) are piecewise
continuous functions of t and the magnitude of the elements
are bounded.Therefore, the coefficients of xi (i = 1,..,n)
and u fulfill the conditions (1) and (2) of Theorem A2.1,
and Theorem A2.3 is used to establish the third condition.
The determinant of the controllability matrix is
Q(x*)=[Po P1 P2 P3 "" ] , (3-16)
where
PO = B
P1 = -AB + B ,
P2 = -AP1
=A2B-2A13-AB+B(2) ,
P3 = -AP2 + P2
=-A3B+2A2i+AAB-AB(2)
+ (A2)'B+A213-2A13-2AB(2)-A(2)B-Ah+B(3)
(3-17)
Since these equations do not generally admit closed-form an-
alytical solutions, it does not appear possible to obtain
explicit representations for this condition.However, by
conjecture, it can be assumed that the controllability ma-
trix is not singular because the elements of the matrix are
not constant, but are a function of states.Therefore, The
system (3-13) is locally totally controllable about the
nominal point.58
3.5 Optimal Control in Tumor Immunotherapy
Cancer cells sometimes display antigens not found on
healthy cells, and so they can potentially activate T-cells
carrying receptors for those antigens.Unfortunately, a de
novo tumor is not usually detected by the immune system in a
natural manner because of the low antigenicity.In this
case, it is assumed that the tumor has been detected through
clinical observation and it is treated with IL-2 dosage.
Generally, cancer patients are treated according to a
discrete IL-2 dosage schedule (e.g., three times a day)
[61].When administered intravenously, IL-2 has a very
short half-life.When IL-2 is administered at 100,000 units
per kg body weight, there is a very rapid fall-off, with an
estimated distribution half-life of 7 to 10 minutes and a
clearance half-life of approximately 30 to 60 minutes [62].
Moreover, a number of clinical studies of the continuous de-
livery of anti-cancer drugs have been reported, and the use
of therapeutic devices to provide continuous delivery is in-
creasing in chemotherapy [63].Experimental results have
also shown that IL-2 induced lymphocytosis is higher with
continuous intravenous administration than for administra-
tion each eight hours [61].Therefore, continuous delivery
of IL-2 was assumed for this analysis.
When a system, for an animal, for instance, is in a
cancerous state, the question is how can appropriate optimal59
therapeutic treatment be administered so that the organism
can resume functioning with its normal attributes?There-
fore, the issue of optimal therapeutic treatment is explored
for this analysis.
The objective of administering IL-2 is to minimize the
size of the tumor cell population at the terminal time of
treatment.The performance functional J is selected to in-
clude the size of the tumor cell population at a selected
terminal time of treatment T, as well as to penalize the ex-
cessive use of IL-2.Let the cost criterion be the integral
square of the deviation of actual tumor size from the de-
sired tumor level with an integral term added to limit con-
trol input and a final term added to insure the proper final
state.The two "costs" may well be different units, i.e.
they are not directly comparable.A parameter w is then
introduced, which enables the weighting of one type of cost.
Thus, a criterion of the form
T
J =[(xii-xlid)2
J
+ wu2(t)]dt + w(xii(T) -xild)2 (3-18)
0
is considered, where u(t) is the input level of IL-2 and T
is the length of a selected treatment interval.The quan-
tity of IL-2 is a time-dependent control variable, repre-
senting the actual size of the IL-2 level used for stimula-
tion of the effector cells at the tumor site.However, the
assumption is made that the IL-2 is approximated to be iden-
tical to the amount of IL-2 infused.xild, which is the60
maximum allowable tumor size without threatening the life of
the patient, is a safe tumor size (i.e., the desired level).
The constant W is chosen to weight the terminal condition as
desired.Since the purpose of an optimal IL-2 regimen is to
minimize J, which corresponds to the achievement of a low-
total final population while restricting the amount of IL-2
in use, there is a tradeoff between the final population and
the amount of IL-2 administered.
Thus, assume that the state equations of the immune
system to be considered are of the form
x(t) = f(x,u):x(t0) = x0 . (3-19)
The problem, then, is to minimize the performance functional
J expressed by Eqn. (3-18), subject to the dynamics of the
system given by Eqn. (3-19).
To accommodate a criterion of the form provided in Eqn.
(3-18), the system differential equations are augmented by
an additional equation, defining a new state variable x13,
which satisfies
x13 = (x11 xl1d)
2+ wu2: x13(0) = 0 . (3-20)
For x13 defined in this manner
J. = x13(T) + W(x11(T)-xl1d)2 = 0(x(T))
. (3-21)
It is desired to determine the optimal control law.
The Hamiltonian is
H(x,u,X) = XT(t) f(x,u) . (3-22)
The costate equation is61
aH
A(t) = - (3-23)
ax
The adjoint system is then evaluated with terminal condition
X(T) = Vx0, (3-24)
with the Vx0 evaluated at t = T.
The system of interest in this analysis, Eqn.(3-19),
is programmed forward in time from the given initial condi-
tions on the state variables and for the given control func-
tions, using Runge-Kutta fourth-order method.The resulting
state trajectory x is then stored for next step.The
adjoint system is also integrated backwards in time from the
terminal condition.Using the gradient over [0,T], the
conjugate gradient descent method is carried out to obtain
an optimal input iteratively.As previously noted, since
the system is stiff, the step size for integration should be
very small.Therefore, computer memory storage limitations
are crucial to the solution of this problem.
If it is assumed that a cancer patient has about 107
cancer cells present at the time of diagnosis (t = 0), the
goal of cancer immunotherapy would be to reduce this number
to 0.98 x 107 cancer cells within two days.In this case,
the final run involves 10,000 integration steps in a fourth-
order Runge-Kutta integration of the differential equations.
Fig. 3.2 shows the output time response, with the corre-
sponding optimal control input (IL-2) given in Fig. 3.3.C
0
4
0.20.4 0.60.8 1 1.2 1.4 1.6 1.8
TIME [day]
NO IL-2 IL-2 DOSE
Fig. 3.2Output response.
a5-
3
25
U,002
1.5-
1
0.5
0 0.2 0:4 0:6 0'.8 1 1 :2 1'4 1 :6 1'8
TIME [day]
Fig. 3.3Optimal control input.
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The optimal IL-2 dose is initially set at the maximum,
and then decreased until the end of treatment.During
treatment, the number of tumor cells is increased due to the
initial lack of effector cells.Subsequently, the number of
tumor cells is regressed by the immune system (i.e., 0.98 x
107cancer cells at 2 days).
This is only a theoretical investigation for cancer
immunotherapy using IL-2. More practical consideration such
as how to maintain IL-2 level, is not considered in this
research. Also the IL-2 level at the tumor site is not the
same as the prescribed IL-2 dose. However, it is assumed
here that the IL-2 level used is identical to the amount of
IL-2 infused.
Following treatment, it is certain that the tumor will
grow again.Therefore, the tumor population must be main-
tained below an allowable limit, and not just during the
treatment period. Of course theoretically, the required
terminal control for maintaining a controllable tumor can be
computed from the system equations. But now the tumor again
continues to grow after tf, and further treatment repeated
until the immune system ultimately (and hopefully) takes
control.64
3.6 Parameter Sensitivity Analysis
The plausibility of the model with respect to its com-
plexity and the interrelationship between the model struc-
ture and the parameter values can be assessed quantitatively
by the use of sensitivity analysis.In order to examine the
effects of parameter uncertainty on model plausibility, it
is necessary to test the sensitivity of the predicted model
responses to the numerical values of the parameters.Fur-
thermore, sensitivity analysis can provide insight concern-
ing which of the particular parameters must be specified ac-
curately if the model is to reliably reproduce the patterns
of response observed in a particular subject.In a related
manner, sensitivity analysis may be used to provide guide-
lines for the reduction of complex models by indicating
which of the variables and parameters are essential to the
determination of system behaviors, and hence should be re-
tained in the construct of a simplified model [43].
Sensitivity considerations often play an important role
in the immune system.Since all the system parameters have
properties that change with the environment and with age, it
is not always possible to consider the system parameters as
completely stationary over the entire operating life of the
system.In addition, since only limited knowledge of the
immune system is available and there are difficulties in ob-
taining consistent descriptive data, parameter sensitivity
analysis is employed to systematically investigate the in-fluences of the system parameters.In other words, sensi-
tivity analysis can be used to determine which parameters
must be evaluated precisely and which ones do not.
For parameter sensitivity in a time-varying system,
consider a system described by
ic = f(x,u,a,t) ,
65
x(0) = x0 (3-25)
where x0 is the given initial conditions and x E Rn, u E Rr,
and a E R.The parameter sensitivity of the state x with
respect to the parameter ak is determined by taking the par-
tial derivative of Eqn. (3-25) w.r.t. ak.
af dx(a,t) a
f(x,u,a,t)
aaktdt aak
ax of
where
= Ixf___ -I- ___
aak aak
Jxf
(3-26)
[ afi
for i,j = 1,2,...,n (3-27)
axj
:Jacobian matrix.
dx(a,t) da(t) ax(a,t)
Jax +
dt dt at
where
axi
Jax =[ . for i = 1,...,n,j = 1,...,p
aaj
Substituting Eqn. (3-28) in Eqn. (3-26),
a da(t) ax of _Jax + x
f = J +
Oak dt at Oak Oak
(3-28)
(3-29)and
a da(t) ada(t) aax(a,t)
(jax) + jax
( )+ ( )
Oak dt Oakdt Oakat
Ox Of
f
= u
7
x + (3-30)
Oak Oak
are obtained.Changing the order of differentiation and re-
arranging terms,
66
af a da(t)
=
(jax)
at1a-ak Oak dt
is obtained.
Ox Of
Jx
f
Oak Oak
jax
adaft)
Oak dt
Then, define the vector sensitivity functions
(3-31)
ax
SkE k = 1,2,...,p (3-32)
Oak
and Eqn. (3-31) may be written as
a a da(t) ada(t)
S' = - (Jax) jax
at Oak dt Oak dt
of
+,
x
f ck
Oak
(3-33)
If it is assumed that the parameters at some instant are
constant, then the term
da(t)
dt
is zero.It follows that
a Of
s- Jxf ck 4-
at Oak
(3-34)67
and the initial conditions for Eqn.(3-34) are
axo
sok= (---) k = 1,...,p (3-35)
aak
The state variation 6x can then be obtained as:
6x = [S1, S2, ,SP] 6a . (3-36)
Thus, the influences of parameter variation on the
state variables can be analyzed.If the state variable of
most interest is xi, the variation (5xi is calculated from
Eqn. (3-36) by
P
6xi =
k
I Ski Sak
1
(3-37)
With Eqn. (3-37), it is possible to calculate the vari-
ation on the state variable xi for any parameter variation
at every time instant.To simplify the comparison between
the different parameters, Eqn. (3-37) is scaled with the
steady-state value xis and only the maximum value of
16xi/xis Iis considered and only one parameter at a time
is changed by 10 percent of its nominal value [64,65].
Thus, the sensitivity of each parameter can be compared by
the normalized maximum values and it is calculated as
follows:
6xi
xis
= ISki 'max
max,k Ixis I
I0.1 ak
I
(3-38)
As a numerical example the sensitivity equation is ap-
plied to investigate the influences of system parameters on
the immune system.The nominal values of the parameters68
used for simulation are shown in Table 2.4.To obtain the
vector sensitivity function defined in Eqn.(3-32), the
first-order sensitivity equation expressed in Eqn. (3-34) is
solved using the Runge-Kutta fourth-order method.At each
numerical step, the system state equations are solved to
obtain the Jacobian matrices of 8f /8x and 8f /8a.There are
n(p +l) first-order nonlinear differential equations to be
solved to produce the system states and the sensitivity
functions
The most interesting variable of CMI response is the
population of tumor cell.The influence of each parameter
on the tumor population is obtained by Eqn. (3-38).The
results are introduced with the aid of histograms in Fig.
3.6.The parameter vector a appearing in the system equa-
tion is listed in Table 3.1.
This figure shows clearly which parameters are signifi-
cant and which are not.It is shown that the system is
quite sensitive with respect to variations in macrophage
dynamics (a14,a15,and a23), killing rate (a27 and a28),
tumor growth ratea24,
( )%,and IL-2 (a30).Therefore, careful
attention needs to be paid to select their values.On the
other hand, the influences of parameters of T-suppressor
dynamics (a8, a9, and an) are much lower thah those of
other parameters.This implies that these parameters are
less important for modeling the system.Table 3.1. Parameter vector of the model
a1=71 a16=76
a2=P16 a17=P6
a3=P81 a18=77
(14'72 a19=P7
a5= P27 a20=78
a6= P271 a21=P8
a7= P82 a22=79
a8=73 a23=710
a9=P38 a24=P11
a10=P83 a25=711
all=74 a26=P7,11
a12=P49 a27=P9,11
a13=P49' a28=P10,11
a14=75 a29=712
a15=P5,10 a30=F
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4. SIMULATION AND RESULTS
4.1 Simulation and Results
Experimentation has shown that the multiplicative (or
parametric) control of the tumor by means of individual im-
mune mechanisms results in the increase of the tumor death
rate via the immune effector cells.The slope of the tumor
death rate is very steep.Mathematically, it is a "stiff"
differential equation, and the general solution reflects an
exponential term such as clebx
,b > 0.Using conventional
methods of numerical integration (e.g., the explicit Runge-
Kutta method), a differential equation for this immune model
cannot be effectively solved.
Numerous methods have been developed for the solution
of initial value, ordinary differential equations.For the
"stiff" model, the inference is that an excessively small
step-size requiring excessive computing time must be used to
solve the system equations.Thus, it is important that a
reliable model solver is chosen.As a means to solve gener-
ally stiff systems, the methods most commonly in use are the
semi-implicit Runge-Kutta and the Gear methods [66].For
the current study, the IMSL routine DGEAR is used to inte-
grate the ordinary differential equations.73
Initially, the effects of tumor antigenicity were simu-
lated.As noted in Chapter 2, highly antigenic tumors stim-
ulate the Th cells, producing sufficient IL-2 to generate
the effector cells necessary for the rembval of the target
cells.Fig. 4.1(a) shows that a tumor which has one cell at
an initial time, grows exponentially until sufficient
effector cells appear, then rapidly regresses.It follows
that the immune effector cells have no reason to retain this
quantity of cells.Therefore, the cells decreased in number
in accordance with decreases in the size of the tumor.In
case of lower antigenicity, there was an absence of
sufficient quantities of IL-2 and concentrations of the
effector cells remained the same as in the healthy state
(Fig. 4.1(b)).The tumors were no longer be rejected, and
Fig. 4.1(b) indicates a breakthrough phenomenon.In addi-
tion, IFN also plays an important role in the removal of
tumor cells.Fig. 4.1(c) demonstrates progressive tumor
growth when no IFN is produced.In this case, the popula-
tion of Ma decreased exponentially.
In tumor immunology, the final goal is to control the
tumor.Among several methods of immunotherapy, exacerbation
theory provides an effective means to treat tumors.Fig.
4.1(d) shows initial tumor regression due to an increase in
the number of effector cells.However, as the effector
cells were decreased in number, the tumor recurred and8
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Fig. 4.1Tumor dynamics and control:
a) high antigenic tumor,
b) low antigenic tumor,
c) no interferon,
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e) exacerbation theory.
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Fig. 4.1Tumor dynamics and control (continued).77
reached a state of equilibrium growth.At 66 days, 103 tu-
mor cells were injected for two weeks.This higher concen-
tration of tumor cells evoked the stimulation of the effec-
tor cells and completely destroyed the tumor (Fig. 4.1(e)).
The postulated host defense mechanisms against cancer
are obviously ineffective whenever tumor growth occurs.
Several mechanisms have been proposed to explain how tumor
cells escape or evade from destruction by the immune system
and grow unchecked.Of these mechanisms, the most credible
are immunoselection and enhancement [14]:1) the decreased
antigenicity due to the heterogeneous mixtures of different
subclones of tumor cell, and 2) blocking factors of free
tumor antigen or antigen-antibody complexes, which may block
the receptors of the cytotoxic cells and may even enhance
tumor growth.
In addition, it has been proposed that the negative
regulatory influence of tumor-induced suppressor T cells
play an important role in the regulation of the immune re-
sponse to that antigen.In humans, a generalized decrease
of immune competence has been observed during advanced ma-
lignancy.However, whether this decrease can be attributed
to immunological mechanisms or to suppression mediated by
tumor cells is still unclear.Simulation studies show that
suppressor T-cells do not play a crucial role in tumor
escape (Fig. 4.2).There is no difference of effector cell
size between the immune system with higher suppression and78
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with lower suppression.Even though the concentration of
lymphocytes precursor cell is decreased by high suppression
activity, there is no difference in the tumor dynamics.
Therefore, tumor escape is majorly dependent on the anti-
genicity of tumor.
Recent reports have demonstrated that antitumor activ-
ity can be observed for treatments with either a high dose
of IL-2 administered by itself or, due to IL-2 toxicity, a
lower dose of IL-2 combined with lymphokine (IL-2)-activated
killer (LAK) cells [67,68].The same investigations have
also shown that the administration of IL-2 and IFN produces
a substantial synergistic therapeutic effect, and that the
IL-2 effect is synergistic with that of tumor-infiltrating
lymphocytes (TIL).For the current study, Fig. 4.3(a) shows
that the administration of a high dose of IL-2 continuously
to a weakly antigenic tumor at 10 to 15 days can mediate
tumor regression.
The antitumor activity of a combination therapy of low
dose IL-2 and antitumor effector cells as LAK or TIL has
been simulated for weakly antigenic tumors.Fig. 4.3(c)
demonstrates the synergistic antitumor effects of a combina-
tion therapy with IL-2 and Tc cells after 10 days.The ef-
fect of this treatment should be compared with the results
shown in Fig. 4.3(b) for IL-2 when used singly.In similar
fashion, the combined administration of IL-2 and IFN can be
designed to increase therapeutic potency (i.e., compare theHIGH IL-2 DOSE
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a) high IL-2 dose,
b) low IL-2 dose,
c) low IL-2 and Tc dose,
d) low IFN dose after 10 day,
e) low IL-2 and IFN dose at 10 day.
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results indicated in Fig. 4.3(d), reflecting treatment
solely by IFN, with those of Fig. 4.3(e)).
Therefore, satisfactory demonstration simulations of
the model have indicated that it provides a foundation for
the development of a useful tool for the verification of the
results of courses of experimental and clinical immunother-
apy, as well as the formulation of planning treatment
strategies.
4.2 Criticisms of the Model
It is clear that it is not possible to answer either
theoretical or practical questions in tumor immunology by
performing only in vivo or in vitro experiments [69].Math-
ematical models can be an important and helpful tool for the
estimation of the relative importance of selected parameters
applied in experimental systems.
The assumptions included in the development of the
model for this study are included to simply the model and
its methods of analysis.To a certain degree, the data used
for the purposes of simulation is arbitrary.A model can be
considered valid if its performance as expressed in terms of
its output is similar to that of a relevant real-world sys-
tem when the identical inputs are applied to both modes of
analysis.Although the qualitative behavior of the model
regarding tumor dynamics is reasonable, the model awaits
data for model fitting, parameter estimation, or revision of85
the model equations to ensure that the model generates bio-
logically meaningful results.Therefore, the model proposed
in this study should be subject to further verification by
laboratory experimentation.In addition, the high dimen-
sionality of the model (i.e., of the 12th-order), does not
lend itself to the purposes of analytical study.5. CONCLUSIONS AND RECOMMENDATIONS
FOR FUTURE RESEARCH
5.1 Conclusions
86
In this study, a mathematical model of the interaction
between tumor cells and the immune system, or a cell-medi-
ated immunity model, was presented and discussed.It has
been demonstrated that the formulation and testing of this
model provides new insights into selected aspects of tumor
immunology modeling.This investigation has been undertaken
in order to stimulate further contributions to and criti-
cisms of technological developments in this interesting and
exciting area of study. Through the process of model simu-
lation, researchers will be able to gain a more compre-
hensive understanding of the immune system and its rela-
tionship to the growth, analysis, and treatment of tumors.
This study has indicated that optimal control theory
will undoubtedly play a greater role in the immunotherapeu-
tic treatment of a number of tumors.From simulations of
the model for this study, the optimal treatment solution was
determined to be a mixture of an initially large dose of IL-
2 followed by a decrease in IL-2 dosage, and then
administration of a continuous infusion to maintain the
tumor cell population at its allowable limits.87
The parameter sensitivity analysis has been employed to
investigate the influence of system parameters on the CMI
response.It has been found that the high sensitivity
parameters are the macrophage dynamics, killing rate, tumor
growth rate, and IL-2.Therefore, careful attention needs
to be paid to select their values.Contrary to the high
sensitivity parameters, the system is insensitive to the
influences of parameters of T-suppressor dynamics.Based on
the simulation results, the tumor escape mechanism is not
explained by suppression activity.This. phenomenon is
coincident with the sensitivity analysis results
5.2 Recommendations for Future Research
The behavior of the model presented in the current
study could be used to draw general conclusions about the
nature of the CMI response.However, these conclusions
would still constitute insufficient explanations of the com-
plexity of immune system responses to tumors.In general
terms, a great deal of work remains to be done in order to
obtain a working model that will be able to provide compre-
hensive explanations of immune system responses.For in-
stance, there is little kinetic information on cell differ-
entiation and on other factors associated with the killing
of tumor cells.Therefore, more kinetic information is
needed for amore comprehensive model.
Specific recommendations are as follows:88
1)Recent progress in the use of on-line techniques
to study methods of parameter estimation and to
derive the optimal controls from noise-corrupted
observations needs to be put to work for applica-
tions to cancer immunotherapy models.
2)The development of cancerous tissue may be an out-
come of the instability of one or more control
loops.Consequently, further study of control
loops could be used to provide the means to sug-
gest completely new therapies for cancer preven-
tion and/or management.
3)There is a continuing need for new degrees of co-
operation between mathematical modelers and immune
system researchers.
4)Growth coefficients (i.e., differentiation rates,
division rates, and individual cell life) are in-
fluenced by such environmental factors as the sup-
ply of oxygen and nutrients and the presence of
chemical agents, among others.As a result, the
parameters for these coefficients are subject to
random variations over the course of time.There-
fore, the inherent randomness of biological pro-
cesses suggests that the development of stochastic
models would be of great utility.89
BIBLIOGRAPHY
[1]S. A. Rosenberg, Adoptive Immunotherapy for Cancer,
Scientific American, pp. 62-69, May 1990.
[2]S. Brownlee, Immunology's Designer Genes, U.S. News &
World Report, pp. 65-66, Oct. 1989.
[3]R. L. Rawis, In Search to Control Cancer, Understand
Metastasis is Crucial, Chemical & Engineering News,
Vol. 63, pp. 10-17, 1985.
[4]M. Lotze and S. Rosenberg, The Immunologic Treatment
of Cancer, A Cancer J. for Clinicians, Vol. 38, No. 2,
pp. 68-94, 1988.
[5]M. R. Posner and P. Calabresi, Immunotherapy for
Caner, Hospital Therapy, Vol. 12, No. 1, pp. 53-65,
1987.
[6]R. R. Mohler, et al., A Systems Approach to Immunol-
ogy, Proc. IEEE, Vol. 68, No. 8, pp. 964-990, 1980.
[7)A. Rescigno and C. DeLisi, Immune Surveillance and
Neoplasia - -Il: A Two stage Mathematical Model, Bul-
letin of Math. Biol., Vol. 39, pp. 487-497, 1977.
[8]Z. Grossman and G. Berke, Tumor Escape from Immune
Elimination, J. Theor. Biol., Vol. 83, pp. 267-296,
1980.
[9]R. Lefever and R. Garay, A Mathematical Model of The
Immune Surveillance Against Cancer, in Theoretical
Immunology (G. I. Bell, et al. eds.), pp. 481-518,
Marcel Dekker, Inc., NY. 1978.
[10]S. J. Merrill,A Model of the Role of Natural Killer
Cells In Immune Surveillance--II, J. Math. Bio., Vol.
17, pp. 153-162, 1983.
[11]R. J. De Boer, P. Hogeweg, H. F. J. Dullens, R. De
Weger, and W. Den Otter, Macrophage T-Lymphocyte In-
teractions in the Anti-Tumor Immune Response: A Mathe-
matical Model, J. Immunology, Vol. 134, No. 4, pp.
2748-2758, 1985.90
[12]R. J. De Boer and P. Hogeweg, Interactions Between
Macrophages and T-Lymphocytes: Tumor Sneaking Through
Intrinsic to Helper T-Cell Dynamics, J. Theor. Biol.,
Vol. 120, pp. 331-351, 1986.
[13]E. Benjamini and S. Leskowitz, Immunology: A Short
Course, Alan R. Liss, Inc., NY. 1988.
[14]H. C. Stevenson, et al., Tumor Immunology, in
Introduction to Medical Immunology (G. Virella, et al.
eds.), pp. 513-533, Marcel Dekker, Inc., NY. 1990.
[15]J. T. Barrett, Textbook of Immunology: An Introduction
to Immunochemistry and Immunobiology, 5thed., The C.
V. Mosby Co., 1988.
[16]P. Erb, G. Ramila, et al., Role of Macrophages in T
Cell Activation, in Recent Advances in Immunology, pp.
17-22, Plenum Press, NY. 1984.
[17]S. K. Durum, et al., Interleukin 1: An Immunological
Perspective, Ann. Rev. Immunol., Vol. 3, pp. 263-287,
1985.
[18]K. Sikora, Interferon and Cancer, Plenum Press, NY.
1983.
[19]A. Gronberg, et al., Interferon is able to Reduce
Tumor Cell Susceptibility to Human Lymphokine-
Activated Killer (LAK) Cells, Cellular Immunology,
Vol. 118, pp. 10-21, 1989.
[20]R. B. Herberman, Natural Killer (NK) Cells and Their
Possible Roles in Resistance Against Disease, Clinical
Immunology Reviews, Vol. 1, No. 1, pp. 1-65, 1981.
[21]A. Meager, H. Leung and J. Woolley, Assays for Tumor
Necrosis Factor and Related Cytokines, J. Immunologi-
cal Methods, Vol. 116, pp. 1-17, 1989.
[22]K. A. Smith, Interleukin-2, Scientific American, pp.
50-57, March 1990.
[23]W. Greene and W. J. Leonard, The Human Interleukin-2
Receptor, Ann. Rev. Immunol., Vol. 4, pp. 69-95, 1986.
[24]A. O'Garra, et al., B-cell Factors are Pleiotropic,
Immunology Today, Vol. 9, No. 2, pp. 45-57, 1988.
[25]R. B. Herberman,Activation of Natural Killer (NK)
Cells and Mechanism of their Cytotoxic Effects, in
Mechanisms of Lymphocyte Activation and Immune Regula-91
tion (eds. S. Gupta, et al.), pp. 275-283, Plenum
Press, NY. 1987.
[26]B. Bonavida, Molecular Mechanism of Natural Killer
Cell-Mediated Cytotoxity, in Mechanisms of Lymphocyte
Activation and Immune Regulation (eds. S. Gupta, et
al.), pp. 299-307, Plenum Press, NY. 1987.
[27]W. D. Otter, H. Dullen, and R. Weger, Macrophages and
Antitumor Reactions, Cancer Immunology Immunother.,
Vol. 16, pp. 69-71, 1983.
[28]W. D. Otter, Immune Surveillance and Natural Resis-
tance: an Evaluation, Caner Immunology Immunotherapy,
Vol. 21, pp. 85-92, 1986.
[29]W. D. Otter, The Effect of Activated Macrophages on
Tumor Growth in Vitro and in Vivo, Lymphokines, Vol.
3, pp. 389-422, 1986.
[30]E. Klein and F. Vanky, Natural and Activated Cytotoxic
Lymphocytes which Act on Autologous and Allogeneic
Tumor cells, Cancer Immunol. Immunother., Vol. 11, pp.
183-188, 1981.
[31]L. M. Pilarski and J. F. Krowka, Regulation of the
Induction of Cytotoxic T Cells, in Recognition and
Regulation in Cell-Mediated Immunity (Ed. J. D. Watson
et al.), pp. 367-437, Marcel Dekker, Inc., NY. 1985.
[32]R. E. Ballieux and C. J. Heijnen, Some Aspects of T
Cell Regulation in Autoimmune Diseases, in Recent
Advances in Immunology, pp. 183-189, Plenum Press, NY.
1984.
[33]M. E. Dorf and B. Benacerraf, Suppressor Cells and
Immunoregulation, Ann. Rev. Immunol., Vol. 2, pp. 127-
158, 1984.
[34]G. L. Asherson, et al., An Overview of T-Suppressor
Cell Circuits, Ann. Rev. Immunol., Vol. 4, pp. 37-68,
1986.
[35]R. R. Mohler, Foundations of Immune Control and Can-
cer, in Recent Advances in Communication and Control
Theory (Ed. A. V. Balakrishnan), pp. 475-489, Opti-
mization Software, Inc., NY. 1987.
[36]R. R. Mohler and Z. H. Farooqi, On Immune Process
Stochastic Structure, in Theoretical Immunology (Ed.
A. S. Perelson), Vol. II, pt. 1, pp. 327-345, Addison-
Wesley Publ. Co. Inc., 1988.92
[37]S. J. Merrill, Foundations of the Use of an Enzyme-
Kinetic Analogy in Cell-Mediated Cytotoxicity, Math.
Bios., Vol. 62, pp. 219-235, 1982.
[38]A. S. Perelson and C. A. Macken, Kinetics of Cell-
Mediated Cytotoxicity: Stochastic and Deterministic
Multistage Models, Math. Bios., Vol. 70, pp. 161-194,
1984.
[39]C. A. Macken and A. S. Perelson, A Multistage Model
for the Action of Cytotoxic T Lymphocytes in Multicel-
lular Conjugates, J. Immunology, Vol. 132, No. 4, pp.
1614-1624, 1984.
[40]F. B. Hanson and C. Tier, A Stochastic Model of Tumor
Growth, Math. Bios., Vol. 61, pp. 73-100, 1982.
[41]D. Adams, et al., Effector Mechanisms of Cytolytically
Activated Macrophages: II. Secretion of a Cytolytic
Factor by Activated Macrophages and Its Relationship
to Secreted Neutral Proteases, J. Immunology, Vol.
124, No. 1, pp. 293-300, 1980.
[42]M. Sarneva et al., Lymphokine-Activated Killer Cells
in Rats: Generation of NK Cells and LAK Cells from BM
Progenitor Cells, Cellular Immunology, Vol. 118, pp.
448-457, 1989.
[43]E. R. Carson, et al., The Mathematical Modeling of
Metabolic and Endocrine Systems: Model Formulation,
Identification, and Validation, John Wiley & Sons, NY.
1983.
[44]J. A. Berzofsky, et al., Antigen Processing for Pre-
sentation to T Lymphocytes: Function, Mechanisms, and
Implications for the T-cell Repertoire, Immunological
Reviews, Vol. 106, pp. 5-31, 1988.
[45]S. B. Mizel, Interleukin 1 and T Cell Activation, Im-
munological Rev., Vol. 63, pp. 51-72, 1982.
[46]C. Milanese et al., Human T Lymphocyte Activation, in
Mechanisms of Lymphocyte Activation and Immune Regula-
tion (S. Gupta et al., eds.), pp. 59-67, Plenum Press,
NY. 1987.
[47]S. M. Hedrick, et al., T Cell Activation as Determined
by Receptor Occupancy: Implications for Selection of
the Repertoire and Activation in Immune Responses, in
Recognition and Regulation in Cell-Mediated Immunity
(Eds. J. D. Watson, et al.), pp. 149-182, Marcel
Dekker, Inc., NY. 1985.93
[48]J. W. L. Hooton, et al., Interaction of Interleukin 2
with Cells: Quantitative Analysis of Effects, J.
Immunology, Vol. 135, No. 4, pp. 2464-2473, 1985.
[49]K. A. Smith, The Interleukin 2 Receptor, Advances in
Immunology, Vol. 42, pp. 165-179, 1988.
[50]M. Dohlsen, et al., Proliferation of Human CD4 +45R+
and CD4+45R-T Helper Cells is Promoted by both IL-2
and IL-4 while Interferon-Gamma Production is Re-
stricted to IL-2 Activated CD4+45R-T Cells, Immun.
Letters, Vol. 20, pp. 29-34, 1989.
[51]J. Vilcek, et al., Interleukin-2 as the Inducing Sig-
nal for Interferon-Gamma in Peripheral Blood Leuko-
cytes Stimulated with Mitogen or Antigen, in The Biol-
ogy of the Interferon System 1984 (Ed. H. Kichner, et
al.), pp. 385-396, 1985.
[52]R. Scollay and K. Shortman, Cell Traffic in Adult
Thymus: Cell Entry and Exit, Cell Birth and Death, in
Recognition and Regulation in Cell-Mediated Immunity
(Eds. J. D. Watson, et al.), pp. 3-30, Marcel Dekker,
Inc., NY. 1985.
[53]G. Trinchieri, et al., Regulation of Activation and
Proliferation of Human Natural Killer Cells, in Mecha-
nisms of Lymphocyte Activation and Immune Regula-
tion(eds. S. Gupta, et al.), pp. 285-298, Plenum
Press, NY. 1987.
[54]R. Van Furth, et al., The Current View on the Origin
of Pulmonary Macrophages, Path. Res. Pract., Vol. 175,
pp. 38-49, 1982.
[55]I. G. Kevrekidis, et al., Modeling Dynamical Aspects
of the Immune Response: I. T Cell Proliferation and
the Effect of IL-2, in Theoretical Immunology (Ed. A.
S. Perelson), Vol. II, pt. 1, pp. 167-197, Addison-
Wesley Publ. Co, Inc., 1988.
[56]R. R. Mohler, Lecture Notes in Selected Topics of
Systems, Dept. of Elec. Eng., Oregon State University,
Corvallis, OR. 1986.
[57]M. Vidyasagar, Nonlinear System Analysis, pp. 78-88,
Prentice-Hall, Inc., N.J., 1978.
[58]J. Cronin, Differential Equations;' Introduction and
Qualitative Theory, Marcel Dekker, Inc., NY. 1980.
[59]S. A. Rosenberg and M. T. Lotze, Cancer Immunotherapy
Using Interleukin-2 and Interleukin-2 Activated Lym-94
phocytes, Ann. Rev. Immunol., Vol. 4, pp. 681-709,
1986.
[60]R. R. Mohler, Bilinear Control Processes: With Appli-
cations to Engineering, Ecology, and Medicine,
Academic Press, NY. 1973.
[61]J. A. Thompson, et al., Influence of Schedule of In-
terleukin 2 Administration on Therapy with Interleukin
2 and Lymphokine Activated Killer Cells, Cancer
Research, Vol. 49, pp. 235-240, 1989.
[62]S. A. Rosenberg, et al., New Approaches to the Im-
munotherapy of Cancer Using Interleukin-2, Annals of
Internal Medicine, Vol. 108, pp. 853-864, 1988.
[63]K. V. Shepard, et al., Therapy for Metastatic Colorec-
tal Cancer with Hepatic Artery Infusion Chemotherapy
using a Subcutaneous Implanted Pump, J. Clin. Oncol.,
Vol. 3, pp. 161-169, 1985.
[64]M. J. Vilenius, The Application of Sensitivity
Analysis to Electrohydraulic Position Control Servos,
Journal of Dynamic Systems, Measurement, and Control,
Vol. 105, pp. 77-82, 1983.
[65]S. D. Kim, et al., A Parameter Sensitivity Analysis
for the Dynamic Model of a Variable Displacement Axial
Piston Pump, Proc. Instn. Mech. Engrs., Vol. 201, No.
C4, pp.235-243, 1987.
[66]B. Carnahan and J. Wilkes, Numerical Solution of
Differential Equations - An Overview, in Foundations
of Computer-Aided Chemical Process' Design (R. Mah
ed.), Vol. 1, pp. 225-340, Engineering Foundation, NY.
1981.
[67]R. Cameron, et al., Synergistic Antitumor Effects of
Combination Immunotherapy with Recombinant Inter-
leukin-2 and a Recombinant Hybrid a-Interferon in the
Treatment of Established Murine Hepatic Metastases,
Cancer Research, Vol. 48, pp. 5810-5817, 1988.
[68]S. Rosenberg, et al., Combination Immunotherapy for
Cancer: Synergistic Antitumor Interactions of Inter-
leukin-2, Alfa Interferon, and Tumor-Infiltrating Lym-
phocytes, J. of the National Cancer Institute, Vol.
80, No. 17, pp. 1393-1397, 1988.
[69]H. F. J. Dullens, et al., A Survey of Some Formal Mod-
els in Tumor Immunology, Cancer Immunol. Immunother.,
Vol. 23, pp. 159-164, 1986.95
[70]G. W. Swan, Tumor Growth Models and Cancer Chemother-
apy, in Cancer Modeling (J. R. Thompson, et al. eds.),
pp. 91-179, Marcel Dekker, Inc., NY. 1987.
[71]A. K. Laird, Dynamics of Tumor Growth, British J.
Cancer, Vol. 18, pp.490-502, 1964.
[72)L. Simpson-Herren and H. H. Lloyd, Kinetic Parameters
and Growth Curves for Experimental Tumor Systems,
Cancer Chemotherapy Reports, pt. 1, Vol. 54, No. 3,
pp. 143-174, 1970.
[73]L. Norton, A Gompertzian Model of Human Breast Cancer
Growth, Cancer Research, Vol. 48, pp. 7067-7071, 1988.
[74]T. Uede, et al., Functional Analysis of Mononuclear
Cells Infiltrating into Tumors: II. Differential
Ability of Mononuclear cells Obtained from Various
Tissues to Produce Helper Factors that are Involved in
the Generation of Cytotoxic Cells, J. Immunology, Vol.
135, No. 5, pp. 3243-3251, 1985.
[75]E. J. Davison and E. G. Kunje, Some Sufficient Condi-
tions for the Global and Local Controllability of
Nonlinear Time-varying Systems, SIAM J. Control, Vol.
8, No. 4, pp. 489-497, 1970.
[76]E. Kreindler and P. Sarachik, On the Concepts of
Controllability and Observability of Linear Systems,
IEEE Trans. Automatic Control, Vol. AC-9, pp. 129-136,
1964.
[77]L. M. Silverman and H. E. Meadows, Controllability and
Observability in Time-Variable Linear Systems, J. SIAM
Control, Vol. 4, No. 1, pp. 64-73, 1967.APPENDICES96
Appendix 1
Tumor Growth Models
This provides mathematical models for tumor growth.
The simplest growth model is described by the equation [70]:
dN
a N , (A1-1)
dt
i.e., exponential growth at rate a.The solution of this
equation grows like eat.It is essential that there is an
upper limit to the number of cells which can occupy a cer-
tain volume, which perhaps results from a deficiency of sup-
ply nutrients etc..Thus,
dN
(a - bN) N , (Ai -2)
dt
where a and b are positive constants, is an extension of
Eqn. (A1-1).When b = 0, Eqn.(A1-2) reduces to the equa-
tion for exponential growth.Its kinetics obey a logistic
growth curve.The specific growth rate decreases as N in-
creases.
A widely used deterministic tumor cell proliferation is
given by a Gompertz equation of the following form [71,72]:
dN
dt
where
K
b N ln(---)
N
(A1-3)N(t) = the measure of tumor size (i.e., the number of
tumor cells),
K = the maximum tumor size, and
1/b = the length of time required for the specific
growth rate to increase by a factor of l/e
(i.e., the e-folding time).
Gompertz' law provides a better data fit than other
growth laws, both in vitro and in vivo.Thus, the use of
the Gompertz model is empirical, based on data fit.
The solution of the Gompertz Eqn. (A1-3) with initial
value N(0) is
N(t) = N(0) exp[ln( (l_e-bt))
N(0)
97
(A1-4)
However, if the data regarding the largest tumor size
sufficient to kill the patient is unknown, Eqn.(A1-4) is
replaced, using initial growth data as follows:
A
N(t) = N(0) exp[--- (1_e-bt))
b
(A1-5)
where A is the initial specific growth rate.
The number of tumor cells can usually be estimated in-
directly, using the tumor measurements for volume, weight,
or chemical markers.The approximate tumor volume (V) is
calculated as the volume of a sphere or the volume of a rev-
olution of an ellipse by the formula
V = 1/6(7[d3) ,
and98
V = (7[/6) 1w2 ,
where d is diameter, 1 is length, and w is width.It is as-
sumed that a typical tumor of 1 x 109 cells has a mass of
about 1 g and a volume of about 1 ml.
An example of a curve fitted to the data for unper-
turbed T-9 tumor cells is illustrated in Fig. A1.1.The
data fit is based upon the least-squares method applied to
the curve of the tumor cell numbers as a function of the
time of growth.
The first-passage time, the time required for the tumor
to pass from the initial tumor size N(0) to the certain tu-
mor size c, is taken from Eqn. (A1-4) as follows:
1 ln(K/c)
tc = - --- ln[ ] . N(0) < c < K (Al -6)
b ln(K/n(0))
Fig. A1.2 illustrates tc as a function of initial tumor size
and b, where tc is the time required for a tumor to grow
from one cell to a size large enough to be detected clini-
cally, or 1 x 109 - 5 x 109cells [73].600
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Fig. A1.1Unperturbed T-9 tumor dynamics.
The line with square is the fit of the Gom-
pertz model to the transplanted T-9 tumor
cells into Fisher rats [74].The data has
been modified by converting the tumor size
to a cell number.The estimated parameters
are:
A
b = 0.2755933, A = 2.919033.
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APPENDIX 2
Controllability of Nonlinear Time-Varying Systems
Some results on the controllability of nonlinear sys-
terns are presented in this appendix [75].
Consider the nonlinear time-varying system with linear
control represented by the equation
dx/dt = A(t,x)x + B(t,x)u , t0 < t < co (A2-1)
where the state x is an n-vector, the control input u an m-
vector, A is an n x n and B an n x m matrix.Assume that
the elements aik(t,x) of A (i,k = 1,2,3,...,n) and the ele-
ments bil(t,x) of B (i = 1,2,3,...,n, 1 = 1,2,3,...,m) are
continuous functions of x for fixed t and piecewise continu-
ous functions of t for fixed x, and fulfill the following
conditions:
laik(t,x)I < M,Ibit(t,x)I < N
for all x E Rn, t E [to,tf] , (A2-2)
where M and N are positive real constants.
The following definitions are taken' from Kreindler and
Sarachik [76].
Definition A2.1.The system expressed by Eqn. (A2-1)
is said to be completely state controllable at t0
in the domain of controllability, D C Rn, if each
initial state x(t0) in D can be transferred to any
final state xf in D in some finite time tf(xf)102
to.(If D is the whole state space Rn, the con-
trollability is said to be global;if D is not
the whole of Rn, the controllability is said to be
local.)
Definition A2.2.The system expressed by Eqn. (A2-1)
is said to be totally state controllable in the
domain of controllability D if it is completely
state controllable in D on every interval [to,tf],
tf > t0.(If D is the whole of Rn, the controlla-
bility is said to be global, otherwise it is said
to be local.)
To derive sufficient conditions for the controllability
of the system expressed by Eqn. (A2-1), first consider the
simpler system
dx/dt = A(t,z)x + B(t,z)u , (A2-3)
where the argument x of A and B has been replaced by a spec-
ified function zECn[to,tf], the Banach space of continuous
Rn-valued functions on [to,tf].For each fixed z E
Cn[to,tf], the system expressed by Eqn.(A2-3) is lineai-;
and with x(to) = x0, the solution is given by
it
x(t) = 0(t,to;z)x0 +0(t,7;z)B(7,z)u(r)d7 . (A2-4)
to
In Eqn. (A2-4), 0(t,t0;z) is the state transition matrix of
the system
dx/dt = A(t,z)x (A2-5)
and is determined by103
where
d
0(t,t0;z)= A(t,z)0(t,t0;z), 0(to,to;z)
identity matrix.Then, define
= I ,(A2-6)
dt
I is the
H(to,r;z)= 0(to,r;z)B(r,z) , (A2-7)
and
It
G(to,r;z)= H(t0,7;z)111(to,r;z)dr .
Jto
(A2-8)
The prime indicates the matrix transpose.
The necessary and sufficient conditions for the system
expressed by Eqn. (A2-3) to be controllable are summarized
by the following lemmas [76].
Lemma A2.1.The system expressed by Eqn.(A2-3) is
completely state controllable at to if and only if
there exists a finite time tf > to such that the
rows of the matrix H(to,r;z) are linearly indepen-
dent functions of T on [to,tf].
Lemma A2.2. The system expressed by Eqn. (A2-3) is to-
tally state controllable if and only if for all to
and for all tf > to the rows of matrix H(to,r;z)
are linearly independent functions of 7 on
[to,tf].
The following theorem gives the conditions under which
the nonlinear system expressed in Eqn.(A2-1) is globally
controllable.
Theorem A2.1 (Global controllability).The system
dx/dt = A(t,x)x + B(t,x)u is globally (a) completely state
controllable at to or (b) totally state controllable if the
following three conditions hold:104
1)The elements aik(t,x) of A (i,k = 1,2,...,n) and
bil(t,x) of B (1=1,2,...,m, i=1,2,...,n) are
piecewise continuous functions of t and continuous
functions of x;
2)laik(t,x)I < M, Ibil(t,x)I 5,N, for all x E Rn,
t E [to,tf], where M and N are positive real con-
stants; and
3)There exists a constant c > 0 such that
inf det G(t0,tf;z) > c
zeCn[to,tf]
a)for some tf > to, in the case of complete
state controllability at to, and
b)for all t0 and for all tf > to, in the case of
total state controllability.
The method used to establish Theorem A2.1 for global
controllability can be used to derive a theorem for local
controllability under less restrictive conditions; i.e., it
will no longer be necessary that the elements of A and B be
bounded for all x E Rn, and the Gramian determinant need
only have a lower bound on a bounded set, of functions z.
This bounded set is defined by
C =Izlz= Cn[to,tf]; z(t0) = x0, z(tf) = xf;
x0, xf ERn; IIz
0< K1 } , (A2-9)
where K1 is some real positive nonzero constant.
Theorem A2.2 (Local controllability).The system
dx/dt = A(t,x)x + B(t,x)u is locally,(a) completely state105
controllable at to or (b) totally state controllable about
the origin if the following three conditions hold:
1)The elements aik(t,x) of A (i,k = 1,2,...,n) and
bil(t,x) of B (1 = 1,2,...,m, i = 1,2,...,n) are
piecewise continuous functions of t and continuous
functions of x;
2)laik(t,z)I < M, Ibil(t,z)I < N for all
z E C, t E [to,tf], where M and N are positive
real constants; and
3)inf det G(to,tf;z) > c for some c > 0
zEC
a)for some tf > to, in the case of complete
state controllability at to, and
b)for all to, and for all tf > to, in the case
of total state controllability.
Relation of Gramian Matrix to Controllability Matrix
A serious difficulty in the application of Theorems
A2.1 or A2.2 is to show that condition (3) holds.There-
fore, a relation which shows that condition (3) holds (for
certain cases) is given.
If the additional assumption is introduced that A(t,z)
and B(t,z) are piecewise differentiable on [to,tf], at least
n-2 and n-1 times, respectively, then the controllability
matrix Q of Silverman and Meadows [77] can be introduced.
Define the matrix106
Q(t;z,z(1) ,...,z(n-1))=[Po(t;z),P1(t;z,z(1)),...,
(1),...,z(n-1) Pn_1(t;z,z (A2-10)
where Pk(t;z,z(1),...,z(k)) is recursively defined by
Pk(t;z,z(1) ,..,z(k))= -A(t,z)Pk_1(t;z,z(1),..,z(k-1))
d
Pk-1(t;z,z(1),...,z(k-1).)
dT
and
(A2-11)
P0(t,z) = B(t,z) . (A2-12)
For simplicity, denote Q(t;z,z(1),...,z(n-1)) by Q(t,z).
Theorem A2.3.Assume that A(t,z) and B(t,z) of (A2-3)
are piecewise differentiable on [to,tf], at least
n-2 and n-1 times, respectively, and that B(t,z)
is an n x 1 vector.If
inf det Q(t,z)]2 >y for some 7 > 0
zECn[to,tf](or C)
and for some t in [ta,ts], where [ta,tfl] is a
subinterval of [to,tf], then det G(ta,tivz) of
Theorems A2.1 and A2.2 have a lower bound such
that inf det G(ta,tvz) > C for some
zECn[to,tf](or C)
E > 0.